


CORRECTED VERSION(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 January 2002 (31.01.2002)**PCT**(10) International Publication Number
WO 02/07742 A2(51) International Patent Classification⁷: **A61K 35/74**Gaithersburg, MD 20870 (US). **SCHOLL, Deal** [US/US];
10416 Fawcett Street, #2, Kensington, MD 20895 (US).(21) International Application Number: **PCT/US01/23390**(22) International Filing Date: **25 July 2001 (25.07.2001)**(74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson
and Bear, LLP, 16th floor, 620 Newport Center Drive, New-
port Beach, CA 92660 (US).(25) Filing Language: **English**(26) Publication Language: **English**(30) Priority Data:
60/220,987 25 July 2000 (25.07.2000) **US**(71) Applicant (for all designated States except US): **THE
GOVERNMENT OF THE UNITED STATES OF
AMERICA**, as represented by **THE SECRETARY,
DEPARTMENT OF HEALTH AND HUMAN SER-
VICES** [US/US]; National Institutes of Health, Office of
Technology Transfer, Suite 25, 6011 Executive Boulevard,
Rockville, MD 20852-3804 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE
(utility model), DK, DK (utility model), DM, DZ, EC, EE,
EE (utility model), ES, FI, FI (utility model), GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW.

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MERRIL, Carl, R.**
[US/US]; 6840 Capri Place, Rockville, MD 20817 (US).
ADHYA, Sankar [US/US]; 14400 Kings Grant Road,
Gaithersburg, MD 20870 (US).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).*[Continued on next page]*(54) Title: **BACTERIOPHAGE HAVING MULTIPLE HOST RANGE**

(57) Abstract: The present invention discloses compositions and methods for the prophylaxis and treatment of bacterial infections by the use of polyvalent bacteriophage having multiple host range.

WO 02/07742 A2

**Published:**

- *without international search report and to be republished upon receipt of that report*
- *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(15) Information about Correction:

see PCT Gazette No. 16/2002 of 18 April 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(48) Date of publication of this corrected version:

18 April 2002

Bacteriophage Having Multiple Host Range

Field of the Invention

5 The present invention discloses compositions and methods for the prophylaxis and treatment of bacterial infections by the use of polyvalent bacteriophage having multiple host range.

Background of the Invention

10 *Escherichia coli* capsular polysaccharides (K antigens) have often been associated with increased virulence (17). The K1 antigen in particular increases the invasiveness of *E. coli*, and these strains are often involved in cases of meningitis and septicemia (32). These polysaccharide coats also act as recognition sites for bacteriophages, which often carry tail spikes that contain polysaccharide depolymerization activities. Several K1 specific phages have been described (10), one
15 of which, Φ K1E, was found to possess N-acetylneuraminidase (endosialidase) as a part of the tail fiber protein (37). This enzyme catalyzes the cleavage of α -2,8-linked poly-N-acetylneuraminic acid carbohydrate polymer of the K1 capsule. It has been suggested that the tail fiber protein is involved in both adsorption to the cell surface and penetration into the cell by enzymatically degrading the polysaccharide capsule. The
20 Φ K1E endosialidase gene has been cloned and sequenced (20). A similar gene has been cloned and sequenced from Φ K1F (29).

Φ K5 is a related bacteriophage specific for *E. coli* strains that display the K5 antigen, a polymer consisting of a repeating structure of 4-linked α -N-acetylglucosamine and β -glucuronic acid (N-acetyl heparosin). In this case, Φ K5 encodes a tail associated
25 K5 specific lyase protein that is also responsible for attachment to the cell surface and degradation of the K5 polysaccharide capsule (12,14). Phage have also been found that are specific for other *E. coli* polysaccharide antigens including K3, K7, K12, K13, and K20 (26,27); all probably possess specific polysaccharide depolymerization activities as part of the phage particle.

Both $\Phi K5$ and $\Phi K1E$ have a *Salmonella* phage SP6-like promoter upstream of their tail proteins as well as a region of sequence similarity, which is just downstream of the lyase gene of $\Phi K5$ and just upstream of the endosialidase gene of $\Phi K1E$ (6). The sequences upstream of the tail gene promoters in $\Phi K1E$, and $\Phi K5$ are highly similar as well. $\Phi K5$, $\Phi K1E$ and SP6 share a common morphology and life cycle, suggesting that they may be closely related.

Antibiotics superseded the potential use of bacteriophage in the treatment of infections. The extensive use of antibiotics has led to antibiotic-resistant bacterial pathogens. Thus, investigators have reassessed bacteriophage therapy and prophylaxis. However, one major obstacle that is frequently raised to the use of bacteriophage is that of their excessively narrow host range. There is a need for bacteriophage having multiple host range for use in therapy and prophylaxis.

Summary of the Invention

A virulent double stranded DNA bacteriophage, $\Phi K1-5$ has been isolated and was found to be capable of infecting *E. coli* strains that possess either the K1 or the K5 polysaccharide capsule. Electron micrographs show that the virion consists of a small icosahedral head with short tail spikes, similar to members of the *Podoviridae* family. DNA sequence analysis of the region encoding the tail fiber protein showed two open reading frames encoding previously characterized hydrolytic phage tail fiber proteins. The first is the K5 lyase protein gene of $\Phi K5$, which allows this phage to specifically infect K5 *E. coli* strains. A second open reading frame encodes a protein almost identical in amino acid sequence to the N-acetylneuraminidase (endosialidase) protein of $\Phi K1E$, which allows this phage to specifically infect K1 strains of *E. coli*. We provide experimental evidence that mature phage particles contain both tail fiber proteins, and mutational analysis indicates that each protein can be independently inactivated. A comparison of the tail gene regions of $\Phi K5$, $\Phi K1E$, and $\Phi K1-5$ shows that the genes are arranged in a modular or cassette configuration. The demonstration that a phage can contain multiple tail proteins that expand its host range is useful in generating phage with broad-spectrum antibacterial properties for therapy and prophylaxis of bacterial infections.

Brief Description of the Drawings

Figure 1. Electron micrograph of Φ K1-5 negatively stained with phosphotungstic acid at a magnification of X115,500. Morphologically this phage and can be classified in the *Podoviridae* family which includes T7 and SP6.

5 Figure 2. Comparison of the coding regions of the tail proteins of Φ K1-5, Φ K5, and Φ K1E. All three phages share sequence similarity in the upstream region (which contains an SP6 promoter) as well as an 85-base intergenic region. Just downstream of the promoter, Φ K1-5 and Φ K5 encode a lyase protein and Φ K1E encodes ORF_L. Immediately following the termination codons of the lyases or ORF_L is
10 the intergenic region that contains a potential hairpin structure, the first of which could be a Rho-independent transcription terminator. Immediately following this, Φ K1-5 and Φ K1E encode an endosialidase where Φ K5 encodes ORF_P. None of the three phages have any coding regions downstream, and the DNA molecule ends in all three cases. No sequence similarity exists in this terminal region.

15 Figure 3. Two possible models for the arrangement of the tail proteins on the phage capsid. (a) There are three copies of each tail forming a hexamer. (b) There are six copies of each tail. One is attached to the head and is part of the "core" of the tail. The other is then attached to the first tail protein, in effect making a longer tail fiber with two different enzymatic activities.

20 Figure 4. Comparison of the coding regions of the tail proteins of Φ K1-5, Φ K5, Φ K1E, and SP6.

Brief Description of the Sequences

SEQ ID NO:1 is the DNA sequence of the tail gene region of Φ K1-5.

25 SEQ ID NO:2 is the DNA sequence of Φ SP6 tail gene.

SEQ ID NO:3 is the DNA sense sequence of Φ K1-5.

SEQ ID NO:4 is the DNA antisense sequence of Φ K1-5.

Brief Description of the Biological Deposits

5 Φ K1-5 was deposited as ATCC Accession No. PTA-3495 on July 2, 2001 with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, USA. This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from date of deposit. The deposit will be made available by ATCC under the terms of the Budapest Treaty, and 10 subject to an agreement between Applicant and ATCC which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be 15 entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14). Availability of the deposited strain is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

Detailed Description of the Preferred Embodiment

20 We have discovered that it is possible to express more than one host specific tail protein in a single bacterial viral strain and that expression of these tail proteins permits the virus to infect multiple specific hosts. This discovery facilitates the genetic engineering of phage with expanded host ranges. For example, there are phage that can 25 infect *E. coli* strains that contain the K1 polysaccharide in their outer capsule. Such *E. coli* bacterial strains are often involved in meningitis and septicemia, as K1 polysaccharide increases the invasiveness of the bacteria (32). A phage (Φ K1E) possesses a tail protein with endosialdase activity that can infect strains of *E. coli* containing the K1 polysaccharide. This endosialdase allows the phage Φ K1E to

specifically attach and degrade the K1 polysaccharide (37). Similarly, phage Φ K5 can infect K5 strains of *E. coli*. The K5 strains of *E. coli* are commonly a cause of urinary tract infections (11). The phage Φ K5 contains a tail protein that has lyase activity that allows this phage to attack the bacterial K5 capsule (12, 14). We have demonstrated that it is possible for a phage to have both tail proteins, the K1 endosialdase as well as the K5 lyase. Such a phage, which we have designated phage Φ K1-5, has an expanded host range as it can infect both *E. coli* K1 and *E. coli* K5. We have demonstrated that this expanded host range capability is due to the capacity of this Φ K1-5 phage to display both tail proteins, a K1 endosialidase as well as a K5 lyase. We have demonstrated through sequence analysis of Φ K1-5 phage tail protein genes that they are arranged in a modular or cassette structure, indicating that the host range of phages can be broadened for other K antigens, and even other bacteria species by recombinational techniques. The demonstration that a phage can contain multiple tail proteins that expand its host range is envisioned as being useful in generating phage with broad-spectrum antibacterial properties for the therapy and prophylaxis of infectious diseases. Recently there has been a renewed interest in the use of phages to treat and prevent bacterial infections (for a review see Barrow and Soothill, 1997, *Trends Microbiol.* 5(7), 268-271). Φ K1-5 is highly lytic, non-lysogenic, very stable, and kills bacteria rapidly, all features that make it a good candidate for phage therapy. The phage Φ K1-5 has an additional advantage because it recognizes and attaches to the same structure(s) that confer virulence to the bacteria. In addition, bacteria that become resistant to phage usually have lost the polysaccharide capsule and are no longer virulent. Given these findings, Φ K1-5 is envisioned as being used as a general platform phage for therapeutic and prophylatic applications in which host specificity will be altered by engineering the tail protein genes. The capacity to engineer the expression of tail proteins is also envisioned as providing for phage that can transfer genes to organisms that are not normally infected by phage. Such a goal is to be achieved by expressing a mammalian viral protein on the tail of the phage to enable such a phage to transfer its genetic material into a mammalian cell. Phage with this capability will be of use in gene therapy applications.

Referring to Figure 1, Φ K1-5 is an isolated bacteriophage consisting of an icosohedral head with a small tuft of short tail fibers that is able to infect and replicate on either K1 or K5 strains of *E. coli*. It appears that its ability to replicate on these strains is due to the fact that it encodes two different hydrolytic tail fiber proteins. One is an endosialidase protein, almost identical to a similar protein from Φ K1E, that allows it to attach to and degrade the K1 polysaccharide capsule. The other is almost identical to a lyase protein that has been shown to allow Φ K5 to attach to and degrade the K5 polysaccharide capsule. This is the first example of a phage that has a dual host specificity based on having two different tail proteins.

Referring to Figure 2, all three of these phages share sequence similarity upstream of the region encoding the tail proteins and all have an Φ SP6-like promoter that probably drives transcription of the tail gene(s). In Φ K1-5 and Φ K5, the first gene downstream of this promoter is the K5 lyase protein. Φ K1E does not encode this protein and instead has a 111 amino acid ORF (ORF_L) of unknown function. Immediately downstream of the K5 lyase proteins of Φ K1-5 and Φ K5, and downstream of ORF_L in Φ K1E is an 85 base region of similarity between all three phages. This region contains two strong symmetrical elements that may be involved in transcription termination. Further downstream, phages Φ K1-5 and Φ K1E encode the endosialidase gene. Φ K5 does not encode this gene but instead encodes the 523 amino acid ORF_p .

Φ K1-5 is a bacteriophage that we isolated from sewage using a K5 strain of *E. coli* as a host. By analyzing the host range of Φ K1-5, we found that it can replicate on either K1 or K5 strains. DNA sequence analysis of the tail fiber genes revealed that it encodes both a K5 lyase protein similar to that of Φ K5 and an endosialidase protein similar to that of Φ K1E. The arrangement of these genes indicates that phage host range can be broadened or changed by the acquisition of new tail genes by recombination in nature or by technology in the laboratory.

Φ K5 also is able to replicate on K95 strains of *E. coli* (28). Since ORF_p is in a position analogous to that of the endosialidase of Φ K1-5, it is also envisioned as a tail protein responsible for growth on K95 strains. Another K antigen specific phage, Φ K20, is also able to lyse two different types of *E. coli* hosts, those that possess the K5 antigen and those that possess the K20 polysaccharide (26). We envision Φ K20 as

carrying a K5 lyase protein similar to the Φ K5/ Φ K1-5 protein along with a K20 specific hydrolytic tail protein. Phages have also been isolated that are specific to the capsular antigens K3, K7, K12, and K13 of *E. coli*. Presumably these phages have corresponding K specific hydrolytic tail proteins. We envision other phages having multiple specificities with other combinations of K antigens.

The host range of a bacteriophage is expanded beyond *E. coli* by expressing the genes encoding multiple different host tail proteins, a constraint being an understanding of the mechanism by which the tail protein is attached to the capsid structure of a phage. The N-terminus of the T7 tail protein is thought to be involved in attachment (29). Neither the endosialidase nor the K5 lyase has this region, or any other region similar to any other tail protein (or with each other). Morphologically, Φ K1E, Φ K5 and Φ K1-5, are similar to *Salmonella* phage P22. The tail protein of P22 has been extensively studied and is also a hydrolytic protein involved in degradation of the *Salmonella* typhimurium O antigen. This protein is a homotrimer with six copies per phage (30). The gp17 tail-fiber of T7 is also a trimer with 6 copies of the trimer per phage particle (33). The endosialidase of Φ K1E is also a trimer (20), but it has yet to be shown that there are 6 copies of the trimer per phage particle. Bacteriophage 63D is another newly characterized sialidase containing phage in which it has been shown by electron microscopy that the sialidase is present with 6 copies per particle (21). This phage is quite different morphologically from Φ K1E, Φ K5, and Φ K1-5 and has a long tail similar to that of bacteriophage lambda, with the sialidase located at the end of the tail. Six copies of a trimeric tail protein appear to be a general structural motif. Assuming that the endosialidase and K5 lyase are also arranged in six copies per virion, it is interesting to speculate how the two tail proteins are arranged on the head structure of Φ K1E. They may be arranged in an alternating fashion where there are three copies of each (Figure 3a). In the case of P22, there is evidence that only three copies of the tail are needed for infection (16) suggesting that this model is theoretically possible. The fact that there are no common sequence similarities between the two tail proteins argues against this model, since one might predict a common motif within the tail proteins that is required to attach to similar regions of the head structure. An alternative model is that there may be 6 copies of each tail protein, one attached to the other (Figure 3b). Since

the N-terminus of the T7 tail protein is thought to be involved in attachment of the tail protein to the head structure, this region of the protein and similar regions of other tail proteins (or alternative regions of tail proteins that mediate attachment of one to the other) are envisioned as serving the attachment function, so an understanding of the mechanism no longer acts as a constraint.

Our findings indicate that phages Φ K5, Φ K1E, and Φ K1-5 all share a region of sequence similarity upstream of the tail proteins. This region contains a *Salmonella* phage SP6 promoter. The DNA sequence surrounding the promoter described in Nam et al., Gene 1986, 46:57 matched the analogous sequence in Φ K1-5. Based on this information, we designed a primer from this region to sequence downstream of the analogous region in phage Φ SP6. DNA sequencing identified an open reading frame that has a high degree of amino acid similarity to phage P22 tail protein. Φ P22 is a well characterized *Salmonella* phage that has a similar morphology to Φ SP6, but has a very different life cycle. (Φ P22 is lysogenic like *E. coli* phage lambda, and Φ SP6 is lytic like T7 or the three K antigen phages). The P22 tail protein also has a polysaccharide degradation activity. Immediately downstream of the SP6 tail gene lies the 85 base pair intergenic region common to Φ K5, Φ K1E and Φ K1-5, and shortly after that the DNA molecule ends. Figure 4 compares the regions encoding the tail proteins in all four phage. The SP6 tail protein is in the analogous position as the lyase protein of Φ K1-5 and Φ K5 and ORF_L of Φ K1E. Φ SP6 shares the cassette structure of the three K phages, indicating that all four are closely related and differ mainly in the tail proteins. We envision replacing the lyase protein of Φ K1-5 with the SP6 tail to create a phage that can attack *Salmonella* and K1 *E. coli*. It should be easy to construct by homologous recombination because of the common sequence upstream of the tail proteins and the common 85 base sequence between the two tail proteins. An alternative is to create a phage that can attack *Salmonella*, K1 *E. coli* and K5 *E. coli* by designing a construct to encode all three proteins. In the case of Φ K1-5, we have evidence that broad host range evolved by the acquisition of a second specific tail protein. Thus, under the theory of modular evolution, in which duplications and rearrangements of regions within tail fiber genes of different phages seem to mediate changes in host specificity, we envision

increasing host range even further by designing the acquisition of a third specific tail protein, a fourth specific tail protein, and multiple specific tail proteins.

Definitions

5 The term "isolated" requires that a material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring phage present in a natural system is not isolated, but the same phage, separated from some or all of the coexisting materials in the natural system, is isolated.

10 The term "purified" does not require absolute purity; rather it is intended as a relative definition, with reference to the purity of the material in its natural state. Purification of natural material to at least one order of magnitude, preferably two or three magnitudes, and more preferably four or five orders of magnitude is expressly contemplated.

15 The term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated.

Multiple Host Specificity Based On Multiple Different Host Tail Proteins

20 Phage therapy capitalizes on the ability of phage to lyse bacteria. With the increasing incidence of antibiotic resistant bacteria, there is a need to counteract them. The present invention meets that need by overcoming the additional disadvantage frequently raised to the use of phage, which is their excessively narrow host range.

25 A prototype bacteriophage has a head and a tail. The head is an icosahedron. The tail consists of a hollow core. The whole apparatus functions as a syringe for injection of phage DNA into the interior of a bacterial cell. The life cycle is that viral genes are expressed, virions are assembled, and cellular lysis releases infectious particles into the medium. In this way, the bacteriophage kill the host pathogen.

30 One way of evading a host's antibody response is for a bacterium to coat itself with a capsule. A capsule is a network of polymers that is usually composed of polysaccharides, but may be composed of proteins or protein-carbohydrate mixtures,

and that resembles host tissue polymers. In *E. coli*, over 70 different polysaccharide or protein K antigens are currently recognized by the World Health Organization.

5 Bacteriophage carry a tail protein that attaches to a surface structure of a bacterium by which the viral genome enters the infected cell. Some bacteriophage possess a tail protein that contains capsule-degrading enzymatic activity. These enzymes facilitate penetration by bacteriophage of the bacterial cell capsule. In K1 specific bacteriophage, the tail protein is a neuranimidase. In K5 specific bacteriophage, the tail protein is a lyase. In other K specific bacteriophage, the tail protein is another hydrolytic protein.

10 Phylogenetic classification indicates that gram-negative bacteria form one group of bacteria. *Escherichia*, *Shigella*, *Enterobacter* and *Salmonella* are genera of bacteria that are closely related to each other. *Yersinia* and *Vibrio* are the genera next most closely related to the *E. coli* group. *Serratia* and *Klebsiella* are the genera next most closely related to the *E. coli* group. *Campylobacter* is also the genera of Proteobacteria
15 phylum. The genera *Legionella*, *Pseudomonas*, and *Neisseria* are more distantly related. *Bordetella*'s relationship is unknown. *Helicobacter* is the most distantly related genus in the *E. coli* group of gram-negative bacteria. The gram-positive bacteria form another group, with *Listeria* more closely related to the gram-positive cocci *Staphylococcus* and *Streptococcus*, *Enterococcus* and *Clostridium*, than to other gram-positive rods.
20 *Corynebacterium* is most closely related to *Mycobacterium*. The spirochetes *Treponema* and *Borrelia* form a third phylogenetic group, while *Chlamydia* is related more distantly to this group. Despite the genetic diversity represented by pathogenic bacteria, similar strategies for overcoming host defenses have evolved in very different types of bacteria. We contemplate using our invention against but not limited to the
25 following pathogenic bacteria presented in the table below.

Pathogen	Disease	Phage
<i>Escherichia</i>	Hemorrhagic colitis; thrombocytopenia; hemolytic uremic syndrome	+, ATCC
<i>Shigella</i>	Dysentery	+, ATCC
<i>Salmonella</i>	Typhus	+, ATCC
<i>Enterobacter</i>	Urinary tract infections	+, ATCC
<i>Yersinia</i>	Plague	+, ATCC
<i>Vibrio</i>	Cholera; severe diarrhea, rapid dehydration	+, ATCC
<i>Legionella</i>	Legionnaires' disease: malaise, myalgia, fever, headache, respiratory illness	—
<i>Pseudomonas</i>	Opportunistic infections	+, ATCC
<i>Neisseria</i>	Bacterial meningitis	+, ATCC
<i>Bordetella</i>	Pertussis (whooping cough)	+, ref ^a
<i>Helicobacter</i>	Gastritis, peptic ulcers, possibly stomach cancer	+, ref ^b
<i>Listeria</i>	Listeriosis (meningitis)	+, ATCC
<i>Staphylococcus</i>	Abscesses, pneumonia, endocarditis, toxic shock	+, ATCC
<i>Streptococcus</i>	Scarlet fever, rheumatic fever, toxic shock	+, ATCC
<i>Enterococcus</i>	Urinary tract infections	+, ATCC
<i>Clostridium</i>	Tetanus	+, ATCC
<i>Corynebacterium</i>	Diphtheria	+, ATCC
<i>Mycobacterium</i>	Tuberculosis: cough, weight loss, lung lesions; infection can spread to other organ systems	+, ATCC
<i>Treponema</i>	Syphilis	+, ref ^c
<i>Borrelia</i>	Lyme disease: rash, fever, neurological and cardiac abnormalities, arthritis	+, ref ^d
<i>Campylobacter</i>	Campylobacter enteritis: abdominal pain, diarrhea, fever	+, ATCC
<i>Chlamydia</i>	Trachoma, genital infections, conjunctivitis, infant pneumonia	+, ref ^e
<i>Haemophilus</i>	Brazilian purpuric fever: purulent conjunctivitis, fever, vomiting	+, ATCC
<i>Serratia</i>	Opportunistic infection in neonates	+, ATCC
<i>Klebsiella</i>	pneumonia	+, ATCC

Where: "+, ATCC" indicates the presence of a corresponding bacteriophage(s) in the ATCC; "+, ref" indicates that information on the existing corresponding bacteriophage can be found in the following scientific literature: ref^a - Holzmayer TA, *et al.* 1988 *Zentralbl Bakteriol Mikrobiol Hyg [A]* 269(2):147-55; Gol'tsmaier TA, *et al.* 1987 *Zh Mikrobiol Epidemiol Immunobiol* 5:9-13; ref^b - Heintschel von Heinegg E, *et al.* 1993 *J Med Microbiol* 38(4):245-9; ref^c - Ritchie AE, *et al.* 1978 *Vet Rec* 103(2):34-5; ref^d - Eggers CH, *et al.* 2000 *J Mol Microbiol Biotechnol* 2(4):365-73; ref^e - Hsia R, *et al.* 2000 *Microbes Infect* 2(7):761-72; Hsia RC, *et al.* 2000 *Microbiology* 146 (Pt 7):1651-60.

In an embodiment of the present invention, a phage has a dual host specificity based on having two different host tail proteins. In another embodiment, a phage has a triple host specificity based on having three different host tail proteins. In a further embodiment, a phage has a quadruple host specificity based on having four different host tail proteins. And so forth, so that in an additional embodiment, a phage has a multiple host specificity based on having multiple different host tail proteins.

In another embodiment of the present invention, a phage having a hydrolytic tail protein has a dual host specificity based on having two different hydrolytic tail proteins. In another embodiment, a phage having a hydrolytic tail protein has a triple host specificity based on having three different hydrolytic tail proteins. In a further embodiment, a phage having a hydrolytic tail protein has a quadruple host specificity based on having four different hydrolytic tail proteins. And so forth, so that in an additional embodiment, a phage having a hydrolytic tail protein has a multiple host specificity based on having multiple different hydrolytic tail proteins.

In another embodiment of the present invention, a phage having a K specific hydrolytic tail protein has a dual host specificity based on having two different K specific hydrolytic tail proteins. In another embodiment, a phage having a K specific hydrolytic tail protein has a triple host specificity based on having three different K specific hydrolytic tail proteins. In a further embodiment, a phage having a K specific hydrolytic tail protein has a quadruple host specificity based on having four different K specific hydrolytic tail proteins. And so forth, so that in an additional embodiment, a phage having a K specific hydrolytic tail protein has a multiple host specificity based on having multiple different K specific hydrolytic tail proteins.

A first example of a phage that has a dual host specificity is Φ K1-5. An example of a phage having a triple host specificity is Φ K1-5 having a third different tail protein. An example of a phage having a quadruple host specificity is Φ K1-5 having a third and fourth different tail protein. And so forth, so that an example of a phage having a multiple host specificity is Φ K1-5 having multiple different host tail proteins.

A second example of a phage that has a dual host specificity is Φ K1E having a second different tail protein, like K1-5. An example of a phage having a triple host specificity is Φ K1E having a second and third different tail protein. An example of a

phage having a quadruple host specificity is Φ K1E having a second, third and fourth different tail protein. And so forth, so that an example of a phage having a multiple host specificity is Φ K1E having multiple different host tail proteins.

5 A third example of a phage that has a dual host specificity is Φ K5 having a second different tail protein, like K1-5. An example of a phage having a triple host specificity is Φ K5 having a second and third different tail protein. An example of a phage having a quadruple host specificity is Φ K5 having a second, third and fourth different tail protein. And so forth, so that an example of a phage having a multiple host specificity is Φ K5 having multiple different host tail proteins.

10 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Escherichia* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*,
15 *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Shigella* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*,
20 *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having
25 different host tail proteins is a phage that infects *Salmonella* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*,
30 *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Enterobacter* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*,
5 *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Yersinia* and additionally infects a
10 bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Vibrio* and additionally infects a
15 bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*,
20 *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Legionella* and additionally infects a
25 bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having
30 different host tail proteins is a phage that infects *Pseudomonas* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*,

Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

5 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Neisseria* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium,*
10 *Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Bordetella* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella,*
15 *Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Helicobacter* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia,*
20 *Haemophilus, Serratia and Klebsiella.*

 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Listeria* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella,*
25 *Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium,*

Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Staphylococcus* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Streptococcus* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Enterococcus* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Clostridium* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Corynebacterium* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Mycobacterium* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Treponema* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Borrelia* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Clostridium*, *Corynebacterium*, *Mycobacterium*, *Treponema*, *Borrelia*, *Campylobacter*, *Chlamydia*, *Haemophilus*, *Serratia* and *Klebsiella*.

Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Campylobacter* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*,

Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

5 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Chlamydia* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium,*
10 *Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Haemophilus* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella,*
15 *Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Serratia* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus,*
20 *Serratia and Klebsiella.*

 Another example of a phage that has a multiple host specificity based on having different host tail proteins is a phage that infects *Klebsiella* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella,*
25 *Helicobacter, Listeria, Staphylococcus, Streptococcus, Clostridium, Corynebacterium,*
30

Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

Host Range Of Phage To Include Bacterial Cells Requiring Co-factors

5 In another embodiment of the present invention, a phage that has a multiple host specificity based on having multiple different host tail proteins additionally has a gene encoding a co-factor that permits it to grow in other types of bacteria. Having the proper tail proteins is necessary for a phage to infect a strain of bacteria, as illustrated by the present experiments. For example, a phage having different host tail proteins is
10 capable of infecting multiple hosts where the host expresses at least one of these host tail proteins. Nevertheless, additional factors may be necessary for a phage to infect other strains of bacteria. The present invention provides these phage where co- factors may also be needed to increase their host range.

 For example the *E. coli* phage lambda does not generally infect *Salmonella*. *E.*
15 *coli* phage lambda requires a functional *E. coli* Nus A gene for lambda promoted transcription/anti-termination of DNA → RNA to permit the virus to replicate and function. As the bacteria *Salmonella* does not have the *E. coli* Nus A gene, lambda cannot grow in *Salmonella*. When the *E. coli* Nus A gene is cloned into the lambda genome, this virus can then infect certain *Salmonella* stains. In a confirmatory
20 experiment, the *E. coli* genome was cut into fragments with restriction enzymes and the fragments cloned into a lambda library. When these lambda phage were plated on *Salmonella*, only those containing *E. coli* Nus A gene grew. Thus, lambda carrying the *E. coli* Nus A gene provides one example of how the host range of a phage can be expanded.

25 In another example of a phage that does not generally infect another type of bacteria, the gene that permits the virus to replicate and function in the bacteria may be known. If known, the gene can be cloned into the viral genome so that this virus can then infect other types of bacteria. If unknown, the gene can be identified, for example, by cutting the bacterial genome into fragments with restriction enzymes and then
30 cloning the fragments into a library of that virus. When these phage are plated on the bacteria, only those containing the gene will grow. Thus, the gene that permits the virus

to replicate and function in the bacteria can be identified. Once the gene is known, virus can be engineered to carry the gene. Thus, the host range of the phage can be expanded even when co-factors are necessary to grow in other types of bacteria.

5 Host Range of Phage To Include Mammalian Cells

In another embodiment of the present invention, a phage has mammalian host specificity based on incorporating the gene for a cell surface-receptor ligand into the phage genome such that it is expressed on the tail of the phage, thus facilitating receptor mediated endocytosis. Poul et al., J Mol Biol 1999, 288:203 and Larocca et al., FASEB J 1999, 13:727 describe gene delivery to mammalian cells by bacteriophage expressing cell surface-receptor ligands as genetic fusions with phage coat proteins or presenting cell surface-receptor ligands on the coats of phage, with the goal being the development of gene therapy vectors. The present invention envisions substituting phage tail proteins.

15 A cell surface-receptor ligand is genetically fused to a phage tail protein or otherwise presented on the tails of phage. Nucleotide sequences encoding ligand-phage fusions or cell surface-receptor ligands themselves may also be modified by insertion of mammalian reporter genes to test for binding, internalization, and expression. Ultimately, the mammalian reporter gene is replaced by a therapeutic nucleotide sequence.

20 The therapeutic nucleotide sequence encodes a factor having a therapeutic effect. In alternative embodiments, a factor is a protein cytocide, an antisense, a ribozyme, a dominant negative mutant, or a therapeutic protein (e.g., a growth factor, a hormone, a cytokine, a receptor, or a ligand). An example of receptor-mediated gene delivery using bacteriophage vectors displaying ligands as genetic fusions with phage coat proteins or presenting cell surface-receptor ligands on the coats of phage is set forth in USP 6,054,312 to Larocca et al.

25 Methods of Making

30 In a different embodiment, the acquisition of new tail genes occurs by recombination in nature. In an alternative embodiment, the acquisition of new tail

genes is generated by technology in the laboratory. Thus, the phage may be developed by selection or engineering.

Phage that have multiple specificities may be selected by assays to determine the host range of phages, such as plaque assays.

5 Alternatively, phage that have multiple specificities may be engineered by cloning the gene for a tail protein into a plasmid vector system and then incorporating this configuration into the phage of interest by an in vivo generalized recombination system in the host bacteria for the phage of interest; or by cloning the gene for a first tail protein into a plasmid vector system, and then cloning the gene for a second tail protein
10 into this carrying vector by in-frame fusion at the 3'- or 5'- end of the gene for the first tail protein, and then incorporating this configuration into the phage of interest by an in vivo generalized recombination system in the host bacteria for the phage of interest; or by cloning the gene for a first tail protein into a plasmid vector system, and then cloning the gene for a second tail protein into this carrying vector by in-frame fusion at the 3'-
15 or 5'- end of the gene for the first tail protein, and then cloning the gene for a third tail protein into this carrying vector by in-frame fusion at the 3'- or 5'- end of the genes for the first and second tail proteins, and so forth, and then incorporating this configuration into the phage of interest by an in vivo generalized recombination system in the host bacteria for the phage of interest.

20

Methods of Using, Formulations, and Administration

The present invention can be applied across the spectrum of bacterial diseases, by selecting or engineering phages, so that phages are developed that are specific for more than one bacterial strain of interest. In that way, a full array of polyvalent
25 bacteriophages is developed for virtually all the bacterial pathogens for man, his pets, livestock and zoo animals (whether mammal, avian, or pisciculture). Phage therapy will then be available:

1) as an adjunct to or as a replacement for those antibiotics and/or chemotherapeutic drugs that are no longer functioning in a bacteriostatic or bactericidal
30 manner due to the development of multi-drug resistance;

2) as a treatment for those patients who are allergic to the antibiotics and/or chemotherapeutic drugs that would otherwise be indicated; and

3) as a treatment that has fewer side effects than many of the antibiotics and/or chemotherapeutic drugs that would otherwise be indicated for a given infection.

5 Another embodiment of the present invention is the development of methods to treat bacterial infections in animals through phage therapy with the polyvalent bacteriophages described above. Hundreds of bacteriophages and the bacterial species they infect are known in the art. The present invention can be utilized to develop polyvalent bacteriophages that can be used to treat any and all infections caused by their
10 host bacteria.

While it is contemplated that the present invention can be used to treat any bacterial infection in an animal and human, it is particularly contemplated that the methods described herein will be very useful as a therapy (adjunctive or stand-alone) in infections caused by drug-resistant bacteria. Experts report (See e.g. Gibbons, A.,
15 "Exploring New Strategies to Fight Drug-Resistant Microbes, Science, 21 Aug. 1993, pp. 1036-38) that at the present time, the drug-resistant bacterial species and strains listed below represent the greatest threat to mankind:

1. All of the clinically important members of the family *Enterobacteriaceae*, most notably but not limited to the following:

20 a) All the clinically important strains of *Escherichia*, most notably *E. coli*. One among a number of candidate wild-type phages against these particular pathogens that could be used as a starting point for the genetic engineering of the present invention would be 0K1-5 having ATCC Accession No. # PTA-3495. (Note: For purposes of brevity, in all the following examples of pathogens, the corresponding wild-type phage
25 will be indicated by the following phraseology: "Example of corresponding phage: ____".)

b) All the clinically important strains of *Klebsiella*, most notably *K. pneumoniae* (Example of corresponding phage: ATCC phage #23356-B1).

c) All the clinically important strains of *Shigella*, most notably *S. dysenteriae*
30 (Example of corresponding phage: ATCC phage #11456a-B1).

- 5 d) All the clinically important strains of *Salmonella*, including *S. abortus-equi* (Example of corresponding phage: ATCC phage #9842-B1), *S. typhi* (Example of corresponding phage: ATCC phage #19937-B1) *S. typhimurium* (Example of corresponding phage: ATCC phage #19585-B1), *S. newport* (Example of corresponding phage: ATCC phage #27869-B1), *S. paratyphi-A* (Example of corresponding phage: ATCC phage #12176-B1), *S. paratyphi-B* (Example of corresponding phage: ATCC phage #19940-B1), *S. potsdam* (Example of corresponding phage: ATCC phage #25957-B2), and *S. pollorum* (Example of corresponding phage: ATCC phage #19945-B1).
- 10 e) All the clinically important strains of *Serratia*, most notably *S. marcescens* (Example of corresponding phage: ATCC phage #14764-B1).
- f) All the clinically important strains of *Yersinia*, most notably *Y. pestis* (Example of corresponding phage: ATCC phage #11953-B1).
- 15 g) All the clinically important strains of *Enterobacter*, most notably *E. cloacae* (Example of corresponding phage: ATCC phage #23355-B1).
2. All the clinically important *Enterococci*, most notably *E. faecalis* (Example of corresponding phage: ATCC phage #19948-B1) and *E. faecium* (Example of corresponding phage: ATCC phage #19953-B1).
- 20 3. All the clinically important *Haemophilus* strains, most notably *H. influenzae* (a corresponding phage is not available from ATCC for this pathogen, but several can be obtained from WHO or other labs that make them available publicly).
- 25 4. All the clinically important *Mycobacteria*, most notably *M. tuberculosis* (Example of corresponding phage: ATCC phage #25618-B1), *M. avium-intracellulare*, *M. bovis*, and *M. leprae*. (Corresponding phages for these pathogens are available commercially from WHO, via The National Institute of Public Health & Environmental Protection, Bilthoven, The Netherlands).
5. *Neisseria gonorrhoeae* and *N. meningitidis* (Corresponding phage for both can be obtained publicly from WHO or other sources).
- 30 6. All the clinically important *Pseudomonads*, most notably *P. aeruginosa* (Example of corresponding phage: ATCC phage #14203-B1).

7. All the clinically important *Staphylococci*, most notably *S. aureus* (Example of corresponding phage: ATCC phage #27690-B1) and *S. epidermidis* (Corresponding phage are available publicly through the WHO, via the Colindale Institute in London).

5 8. All the clinically important *Streptococci*, most notably *S. pneumoniae* (Corresponding phage can be obtained publicly from WHO or other sources).

9. *Vibrio cholera* (Example of corresponding phage: ATCC phage #14100-B1).

10 There are additional bacterial pathogens too numerous to mention that, while not currently in the state of antibiotic-resistance crisis, nevertheless make excellent candidates for treatment with polyvalent bacteriophages in accordance with the present invention. Thus, all bacterial infections caused by bacteria for which there is a corresponding phage can be treated using the present invention.

15 Any phage strain capable of doing direct or indirect harm to a bacteria (or other pathogen) is contemplated as useful in the present invention. Thus, phages that are lytic, phages that are lysogenic but can later become lytic, and nonlytic phages that can deliver a product that will be harmful to the bacteria are all useful in the present invention.

The animals to be treated by the methods of the present invention include but are not limited to man, his domestic pets, livestock, pisciculture, and the animals in zoos and aquatic parks.

20 The polyvalent bacteriophages of the present invention can be used as a stand-alone therapy or as an adjunctive therapy for the treatment of bacterial infections. Numerous antimicrobial agents (including antibiotics and chemotherapeutic agents) are known in the art, which would be useful in combination with polyvalent bacteriophages for treating bacterial infections. Examples of suitable antimicrobial agents and the
25 bacterial infections that can be treated with the specified antimicrobial agents are listed below. However, the present invention is not limited to the antimicrobial agents listed below as one skilled in the art could easily determine other antimicrobial agents useful in combination with polyvalent bacteriophages.

Pathogen	Antimicrobial or antimicrobial group
<u><i>E. coli</i></u>	
Uncomplicated urinary tract infection	trimethoprim-sulfamethoxazole (abbrev. TMO-SMO), or ampicillin; 1st generation cephalosporins, ciprofloxacin
Systemic infection	ampicillin, or a 3rd generation cephalosporin; aminoglycosides, aztreonam, or a penicillin + a penicillinase inhibitor
<u><i>Klebsiella pneumoniae</i></u>	1st generation cephalosporins; 3rd gener. cephalosporins, cefotaxime, moxalactam, amikacin, chloramphenicol
<u><i>Shigella</i></u> (various)	ciprofloxacin; TMO-SMO, ampicillin, chloramphenicol
<u><i>Salmonella:</i></u>	
s. typhi	chloramphenicol; ampicillin or TMO-SMO
Non-typhi species	ampicillin; chloramphenicol, TMO-SMO, ciprofloxacin
<u><i>Yersinia pestis</i></u>	streptomycin; tetracycline, chloramphenicol
<u><i>Enterobacter cloacae</i></u>	3rd generation cephalosporins, gentamicin, or tobramycin; carbenicillin, amikacin, ztreonam, imipenem
<u><i>Hemophilus influenzae:</i></u>	
Meningitis	chloramphenicol or 3rd generation cephalosporins; ampicillin
Other <i>H. infl.</i> Infections	ampicillin; TMO-SMO, cefaclor, cefuroxime, ciprofloxacin
<u><i>Mycobacterium tuberculosis and M. avium-intracellulare</i></u>	isoniazid (INH) + rifampin or rifabutin, the above given along with pyrazinamide +/- ethambutol

Neisseria:

N. meningitidis penicillin G; chloramphenicol, or a sulfonamide

N. gonorrhoeae:

Penicillin-sensitive penicillin G; spectinomycin, ceftriaxone

Penicillin-resistant ceftriaxone; spectinomycin, cefuroxime or cefoxitin, ciprofloxacin

Pseudomonas aeruginosa

tobramycin or gentamycin (+/- carbenicillin, aminoglycosides); amikacin, ceftazidime, aztreonam, imipenem

Staph aureus

non-penicillinase producing penicillin G; 1st generation cephalosporins, vancomycin, imipenem, erythromycin

Penicillinase producing a penicillinase-resisting penicillin; 1st generation cephalosporins, vanco-mycin, imipenem, erythromycin

Streptococcus pneumoniae

penicillin G; 1st generation cephalosporins, erythromycin, chloramphenicol

Vibrio cholera

tetracycline; TMO-SMO

5 In another embodiment of the present invention, the polyvalent bacteria of the invention are provided as compositions useful in the treatment and prevention of various bacterial infections, such as diarrhea, dysentery, hemolytic uremic syndrome, bladder infection, kidney infection, urinary tract infection, septicemia, pneumonia, and meningitis, and other various diseases, syndromes, and disorders.

10 The polyvalent bacteriophage of the invention can be used for the treatment or prevention of *Hemophilus influenza*, *Pseudomonas*, *Streptococcus pneumoniae*, *Streptococcus fasciae*, *Streptococcus* group B, *Listeria*, *Salmonella*, *E. coli*, *Campylobacter*, and other bacteria, and any combination thereof. For example, if there is a bacterial infection of the upper respiratory tract, the infection can be prophylactically or therapeutically treated with a composition comprising at least one

polyvalent bacteriophage specific for that bacteria, and a carrier for delivering the polyvalent bacteriophage to a mouth, throat, or nasal passage. If an individual has been exposed to someone with the upper respiratory disorder, the polyvalent bacteriophage will reside in the mucosal lining and prevent any colonization of the infecting bacteria.

5 Two examples of bacteria which infect the upper respiratory system are *Streptococcus pneumoniae* and *Hemophilus influenzae*. In recent years, there has been an increase in the number of people, particularly children and the elderly, that are infected or are carriers of penicillin resistant *Streptococcus pneumoniae* and *Hemophilus*. While these bacteria are normally harmless residents of the host, they are
10 opportunistic organisms that are able to cause infections when the resistance of the host has been compromised. By eliminating or reducing the number of these organisms in the upper respiratory tract, there will be a commensurate reduction in the number of infections by these bacteria.

 The *Hemophilus* bacteria is infected by bacteriophage HP1 (a member of the P2-
15 like phage family with strong similarities to coliphages P2 and 186, and some similarity to the retronphage Ec67), which produces a lytic enzyme capable of lysing the bacteria. *Streptococcus pneumoniae* is infected with the Pa1 bacteriophage, which produces a lytic enzyme identified as an N-acetyl-muramoyl-L-alanine amidase. The pharmaceutical composition of the invention can contain either one polyvalent
20 bacteriophage that recognizes these two bacteria, and may contain other polyvalent bacteriophage for other bacteria. The composition which may be used for the prophylactic and therapeutic treatment of a strep infection includes the polyvalent bacteriophage and a means of application, (such as a carrier system or an oral delivery mode), to the mucosal lining of the oral and nasal cavity, such that the polyvalent
25 bacteriophage is put in the carrier system or oral delivery mode to reach the mucosal lining. Another infection which can be treated prophylactically is *Streptococcus* group A, which can produce what is commonly known as "strep" throat. Group A *Streptococci* are infected with a C1 bacteriophage, which produces a lysing enzyme specific for the lysing of *Streptococcus* group A.

30 Another use of a polyvalent bacteriophage of the invention is for the treatment of bacterial infections of the digestive tract. The method for treating a bacterial infection

of the digestive tract comprises treating the bacterial infection with composition comprising an effective amount of at least one polyvalent bacteriophage specific for the bacteria, and a carrier for delivering said polyvalent bacteriophage to the digestive tract. In a preferred embodiment of the invention, the bacterial infections being treated are
5 being caused by gram negative bacteria selected from the group consisting of *Listeria*, *Salmonella*, *E. coli*, and *Campylobacter*. However, this method and composition will effectively treat other bacteria, when the appropriate polyvalent bacteriophage is used.

Another composition and use of the polyvalent bacteriophage of the invention is for the therapeutic or prophylactic treatment of bacterial infections of burns and wounds
10 of the skin. The composition comprises an effective amount of at least one polyvalent bacteriophage specific for the bacteria and a carrier for delivering at least one polyvalent bacteriophage to the wounded skin. The polyvalent bacteriophage may be applied to a bandage either directly or in one or another carrier. The bandages may be sold damp or dry, wherein the polyvalent bacteriophage is in a lyophilized form on the bandage. This
15 method of application is most effective for the treatment of burns. In some embodiments of the invention, polyvalent bacteriophage for *Pseudomonas*, *Staphylococcus*, and *Streptococcus*, jointly or individually, may be incorporated into one or another carrier, or into a bandage to be used on burn patients.

Yet another use of polyvalent bacteriophages is for the bacterial infections
20 caused by K1 and/or K5 strains of *E. coli*. These bacteria are involved in a variety of infections, the most common are urinary tract infections (UTI). The polyvalent bacteriophage of the present invention would be applied directly to the site of infection, in the case of UTI this would mean to deliver the phage to the bladder through a catheter.

25 In the case of septicemias caused by K1 *E. coli*, the polyvalent phage of the present invention could be injected directly into the circulatory system or intraperitoneally.

In case of meningitis caused by *E. coli*, the polyvalent phage of the present invention will be delivered to the cerebro-spinal fluid or directly applied to the brain or
30 meninges.

Yet another use of the polyvalent bacteriophages of the invention is for the prophylactic or therapeutic treatment of vaginal infections. This treatment comprises treating the vaginal infection with an effective amount of at least one polyvalent bacteriophages specific for that bacteria, wherein that polyvalent bacteriophages is incorporated in a carrier to be placed in a vagina. The preferred carrier is a tampon, or vaginal douche. A pad may also be used as a carrier, although it is not as effective. While any number of bacteria could be treated using this composition and method, it is believed that the most optimum use of this treatment composition and method would be for the treatment of an *E. coli* and *Streptococcus B* infection. Vaginal infections caused by Group B *Streptococcus* can cause neonatal meningitis resulting in brain damage and premature death. Polyvalent bacteriophages incorporated into tampons specific for group B Strep would eliminate the group B organisms without disturbing normal flora so that women would not be overcome by yeast infections post antibiotic therapy. The use of the polyvalent bacteriophages in the vagina would best provide a prophylactic effect, although therapeutic use would also be advisable.

Another use of the invention is for the prophylactic and therapeutic treatment of eye infections. The method of treatment comprises administering eye drops which comprise an effective amount of at least one polyvalent bacteriophages specific for the bacteria and a carrier capable of being safely applied to an eye, with the carrier containing the polyvalent bacteriophages. In some embodiments of the invention, the bacteria being treated is *Hemophilus* or *Staphylococcus*. The eye drops are in the form of an isotonic solution.

Polyvalent bacteriophages can also be used to fight dental caries. Specifically, a polyvalent bacteriophages specific for *Streptococcus mutans* may be incorporated in a toothpaste or oral wash. Similarly, this polyvalent bacteriophages may also be incorporated into a chewing gum or lozenge. Any other carrier can be used that allows for the exposure of the mouth, gums, and teeth to the polyvalent bacteriophages.

The routes of administration include but are not limited to oral, aerosol, intranasal, intravenous, intramuscular, intraperitoneal, intrathecal, vaginal, rectal, topical, lumbar puncture, and direct application to the brain or meninges. Pharmaceutically acceptable excipients which can be used as a vehicle for the delivery

of the phage will be apparent to those skilled in the art. For example, the free phage could be in lyophilized form and be dissolved just prior to administration by IV injection. The dosage of administration is contemplated to be in the range of about 10^6 to about 10^{13} pfu/per kg/per day, and preferably about 10^{12} pfu/per kg/per day. The phage are administered until successful elimination of the pathogenic bacteria is achieved.

With respect to the aerosol administration to the lungs, the polyvalent bacteriophage is incorporated into an aerosol formulation specifically designed for administration to the lungs by inhalation. Many such aerosols are known in the art, and the present invention is not limited to any particular formulation. An example of such an aerosol is the Proventil™ inhaler manufactured by Schering-Plough, the propellant of which contains trichloromonofluoromethane, dichlorodifluoromethane and oleic acid. The concentrations of the propellant ingredients and emulsifiers are adjusted if necessary based on the phage being used in the treatment. The number of phage to be administered per aerosol treatment will be in the range of 10^6 to 10^{13} pfu, and preferably 10^{12} pfu.

Isolation and Characterization of Φ K1-5

Φ K1-5 was isolated using *E. coli* ATCC 23506 (K5) as a host. Electron micrographs show that Φ K1-5 is morphologically similar to the *Podoviridae* family, which includes coliphages T7, T3, and *Salmonella* phages SP6 and P22. The phage particle consists of an icosohedral head of about 60 nm in diameter with a small tuft of short tail fibers (Figure 1). Φ K1-5 is highly lytic. When phage were added to a logarithmic culture of a susceptible host at an multiplicity of infection (moi) of 1:1, lysis occurs in 15-20 min. Burst size was determined by a one step growth curve and found to be to be about 110. Φ K1-5 plaques are clear and large, about 4.0-5.0 mm in diameter with a halo of about 12.0-15.0 mm in diameter on LB agar plates. The plaques reached a limit in size after 24 hours. In contrast, T7 plaques, can continue to grow for several days (38). DNA was isolated from cesium chloride density gradient purified phage by phenol extraction. Digestion of the DNA with several restriction enzymes indicated that it is double stranded, with an estimated size of 40 kb.

Extended host range of Φ K1-5

The host range of Φ K1-5 was compared to that of Φ K1E (K1 antigen specific) and Φ K5 (K5 antigen specific). *E. coli* strains ATCC 23506 and ATCC 23508 possess the K5 polysaccharide capsule, and strains ATCC 23503 and ATCC 23511 possess the K1 capsule. Also tested was a set of K5 strains collected by Ian Roberts from the University of Manchester and a set of K1 isolates collected by Richard Silver from the University of Rochester (Table 1). Φ K1-5 is able to infect and grow on all of the K1 and K5 strains, Φ K1E only grows on the K1 strains and Φ K5 only grows on the K5 strains. Φ K1E, Φ K5, and Φ K1-5 were also tested for growth on the following ATCC strains: 23502 (K4), 23504 (K8), 23505 (K9), 23507 (K10), 23509 (K11), 23510 (K14), 23515 (K17), 23516 (K20), 23517 (K13), 23518 (K18), 19110 (K7), 19138 (K2) and 31616 (K35). No phage growth by Φ K1-5, Φ K1E or Φ K5 was seen on any of these strains.

TABLE 1. Host ranges of phages Φ K1E, Φ K5, Φ K1-5, Φ K1-5_(K1⁻), and Φ K1-5_(K5⁻)^a

<i>E. coli</i> strain	K antigen	Φ K1-5	Φ K1E	Φ K5	Φ K1-5 _(K1⁻)	Φ K1-5 _(K5⁻)
ATCC 23503	K1	+	+	-	-	+
ATCC 23511	K1	+	+	-	-	+
RS164	K1	+	+	-	-	+
RS166	K1	+	+	-	-	+
RS167	K1	+	+	-	-	+
RS168	K1	+	+	-	-	+
RS176	K1	+	+	-	-	+
RS179	K1	+	+	-	-	+
RS180	K1	+	+	-	-	+
RS188	K1	+	+	-	-	+
RS203	K1	+	+	-	-	+
RS215	K1	+	+	-	-	+
RS218	K1	+	+	-	-	+
RS228	K1	+	+	-	-	+
ATCC 23506	K5	+	-	+	+	-
ATCC 23508	K5	+	-	+	+	-
20026	K5	+	-	+	+	-
21195	K5	+	-	+	+	-
21386	K5	+	-	+	+	-
21786	K5	+	-	+	+	-
21795	K5	+	-	+	+	-
21831	K5	+	-	+	+	-
21832	K5	+	-	+	+	-
21834	K5	+	-	+	+	-
21835	K5	+	-	+	+	-

^aPlaque assays were done to determine host range of the phages against a collection of K1 and K5 strains of *E. coli*. Φ K1E only grows on K1 strains, Φ K5 only grows on Φ K5 strains and Φ K1-5 grows on both. Φ K1-5_(K1⁻) and Φ K1-5_(K5⁻) are mutants of Φ K1-5 defective in growth on K1 and K5 strains, respectively.

Because of the promoter sequence similarity between Φ K1-5 and SP6, we tested if Φ K1-5 could grow on *Salmonella typhimurium* strain LT2 (the host for SP6) and if SP6 could grow on any of the *E. coli* isolates sensitive to Φ K1-5. SP6 did not grow on any of the *E. coli* strains, and likewise Φ K1-5 did not grow on *Salmonella typhimurium*.

Φ K1-5 encodes two tail genes

Φ K1E and Φ K5 share a region of sequence similarity upstream of the tail proteins (including the SP6-like promoter, 3). Since Φ K1-5 had structural, biological and host similarities to these two phages, we speculated that all three may be closely related to and share this upstream sequence similarity. We designed a primer based on the sequence of this region in Φ K1E and Φ K5 to determine the sequence downstream of the promoter. When Φ K1-5 DNA was used as a template, the primer did hybridize, and we were able to generate sequence. We continued sequencing downstream by primer walking. The sequence immediately downstream of the promoter was very similar to Φ K5, and encoded an open reading frame with a high degree of sequence similarity (>92% amino acid identity) to that of Φ K5 tail protein. Continued sequencing downstream revealed a second open reading frame that is nearly identical (>97% amino acid identity) to the endosialidase protein of Φ K1E. An intergenic region of 85 base pairs lies between the termination codon of the lyase gene and the start codon of the endosialidase gene. This region is also present in Φ K5, immediately following the K5 lyase gene, and also in Φ K1E, immediately upstream of the endosialidase gene and immediately downstream of a 111 amino acid open reading frame (ORF_L, 6). No recognizable promoter was found in this region, but there are two strong regions of symmetry, which may act as a Rho-independent transcriptional terminator. Sequence was determined 598 base pairs downstream of the termination codon of the endosialidase gene, at which point the end of the DNA molecule was reached. No open reading frames were found in this area.

The sequence 500 base pairs upstream of the K5 lyase gene in Φ K1-5 was also determined. Like in the other phages, an SP6-like promoter is present and is probably required for transcription of the tail genes. The upstream sequence shares a high degree (>90%) of identity to that of the analogous region in Φ K5 and Φ K1E.

We also sequenced downstream of the endosialidase gene of Φ K1E; 718 base pairs downstream from the endosialidase termination codon we reached the end of the DNA molecule. There is little sequence similarity between this region and the analogous region in Φ K1-5.

Each Φ K1-5 virion contains both tail proteins

We addressed the question of whether Φ K1-5 particles contain both tail fiber proteins, or if two populations of particles (one containing the K5 lyase and the other containing the endosialidase) were produced after infection. We made a phage preparation using ATCC 23506 (K5) as a host and determined its titer on ATCC 23506 (K5) and ATCC 23503 (K1) (Table 2). A sample of the phage was then incubated with ATCC 23506 for 5 min, which is long enough for phage to attach and possibly inject the DNA but not long enough for production of new phage particles. The MOI was 1/100 phage particle/bacteria. The mixture was then rapidly filtered. Phage particles that had attached to the cells would be eliminated from the filtrate. The filtrate was then titered on both the K1 and K5 strains. If the phage preparation was initially a mixture of two populations, then only those displaying the K5 lyase would attach and be eliminated. The remaining phage would be mainly those that contained the K1 specific endosialidase, and therefore the titer would be higher on the K1 *E. coli* strains than on the K5 strain. On the other hand, if each of the phage particles contained both tail proteins, titers of the phage remaining in the filtrate would be the same on the two strains, i.e., levels of the K5 lyase containing phages would not be selectively reduced. We found the latter to be the case and concluded that each virion has both the K1 endosialidase and the K5 lyase. Similar results were seen in the converse experiment in which the 5-min incubation was performed using the K1 *E. coli* strain (Table 2). As controls we performed the experiments with both Φ K1E and Φ K5, using both strains for the incubation. Φ K1E titers were reduced 99% by pre-incubation with the K1 strain but not with the K5 strain, and Φ K5 titers were similarly reduced after pre-incubation with the K5 strain but not with the K1 strain.

TABLE 2. Preincubation experiments to show that all Φ K1-5 particles contain both tail proteins^a

Phage	Titer
Φ K1-5	
Preincubated with 23506	5.2×10^8
Titered on 23506 after preincubation	3.1×10^6
Titered on 23503 after preincubation	3.7×10^6
Preincubated with 23503	5.2×10^8
Titered on 23506 after preincubation	6.8×10^6
Titered on 23503 after preincubation	6.4×10^6
Φ K5	
Preincubated with 23506	4.0×10^8
Titered on 23506 after preincubation	8.5×10^5
Preincubated with 23503	4.0×10^8
Titered on 23506 after preincubation	3.3×10^8
Φ K1E	
Preincubated with 23506	7.7×10^8
Titered on 23503 after preincubation	6.8×10^8
Preincubation with 23503	7.7×10^8
Titered on 23503 after preincubation	3.0×10^6

^aPreincubation of Φ K1-5 with either ATCC 23503 (K1) or ATCC 23506 (K5) for 5 min results in roughly 100-fold loss of phage particles when titered on either strain. If the phage preparation consisted of two populations that each contained just one tail protein, then titers after the incubation would be reduced only on the strain that was used in the preincubation. Φ K5 titers are reduced by preincubation with a permissive host (23506) but not with a nonpermissive host (23503). Φ K1E titers are also reduced only by preincubation on a permissive host (23503) and not a nonpermissive host (23506).

Φ K1-5 mutants defective in growth on either K1 or K5 *E. coli*

A mixed lawn of K1 and K5 strains of *E. coli* was used to screen for Φ K1-5 mutants defective in growth on one or the other host strains. Φ K1-5 forms clear plaques on a mixed lawn of K1 and K5 *E. coli*; mutants in either tail would result in turbid plaques due to growth of the non-permissive host. Phage were treated with the mutagen

hydroxylamine and plated on a double lawn. Turbid plaques were identified, picked, and purified by multiple plaque isolations on the double lawn. These were then screened by separately testing for growth on each strain. Of eight isolates purified, three were unable to plaque on the K5 strain but could plaque on the K1 strain. One of these, $\Phi K1-5_{(K5^-)}$, was screened for growth against the entire host collection and found to be unable to replicate on any of the K5 strains but was able to grow on all of the K1 strains (Table 1). Five of the isolates could still replicate on both K1 and K5 strains but gave a turbid plaque morphology on the on the K5 strains.

None of the mutants isolated in this way were defective in growth on K1 strains, so we devised a selection/amplification scheme to enrich for those that can replicate on K5 but not K1 hosts. Mutagenized phage were amplified on a K5 strain, filtered to remove bacterial debris, then used to infect a logarithmically growing K1 strain for 5 minutes. This mixture was rapidly filtered before phage burst could occur. Phage able to grow on K1 strain would attach to the cells and be eliminated from the filtrate. The sample was then re-amplified on the K5 strain and the cycle was repeated eight times. This strongly selects for phage that can replicate on K5 hosts but not K1 hosts. Titers of the filtrate were 200 fold higher on the K5 strain than on the K1 strain. Several were picked and purified by multiple rounds of single plaque isolation. One isolate, $\Phi K1-5_{(K1^-)}$, was further characterized and found to be unable to grow on any of the K1 strains (Table 1).

DNA sequence of a putative $\Phi K5$ tail gene

Clarke et. al. described a partial sequence of an open reading frame (ORFp) in $\Phi K5$ immediately downstream of the 85 base region common to the three phages (6). We continued sequencing downstream and found the complete open reading frame is 523 amino acids. A BLAST search revealed a small region of sequence similarity with the *N*-acetylglucosamine-permease IIABC component near the N-terminus. It has no significant sequence similarity with any other entry in the database or any of the tail proteins described here. Sequence was determined an additional 163 bases downstream, at which point the end of the DNA molecule was reached.

Figure 2 compares the regions encoding tail proteins in all three phages. Φ K1-5 has a K5 lyase protein in the same position as that of Φ K5. Φ K1E has a 111 amino acid open reading frame (ORF_L) of unknown function in this position. Immediately downstream all three phages have an intergenic region of 85 bases that has two dyad axis of symmetry. Immediately downstream of this region Φ K1-5 encodes its endosialidase protein, which is in the analogous position as the Φ K1E endosialidase. Φ K5 encodes a 523 amino acid open reading frame (ORF_P) in this position. The three phages share sequence similarity upstream of the tail genes. No sequence similarity was noted downstream, and in all three phages the DNA molecule ends downstream.

EXAMPLE 1

Isolation of K1-5

Φ K1-5 was isolated from raw sewage using the plaque technique. Briefly, a 1L sample of sewage was centrifuged at 6000 rpm in a GSA rotor to remove solid matter and was then passed through a 0.45 micron nitrocellulose filter (Nalgene). 100 μ l of filtrate was added to 200 μ l of an overnight culture of *E. coli* ATCC 23506 (K5) grown in LB media. 3 ml of melted tempered top agar (5 g/L agar in LB) was added and the mix was plated onto an LB agar plate and incubated at 37°C overnight. The following day plaques were picked and re-plaqueed 3 times to insure pure culture. Final plaque isolates were stored as an agar plug from a Pasteur pipette deposited in 1 ml of SM buffer (10 mM MgSO₄, 100 mM NaCl, 0.01% gelatin, 50 mM Tris pH 7.5).

Host range was initially screened by spotting 10 μ l of SM buffer containing a plaque plug onto a lawn of an appropriate strain. Host range of interesting phage isolates was further confirmed by the plaque assay. All phage titrations were done by the plaque assay technique.

Large Scale Purification

Phages were prepared by the cesium chloride density gradient method. 1 L of an appropriate host was grown up to an OD 600 of between 0.4 and 0.6 at 37°C with 200 rpm shaking in LB broth. Phage were added at a moi of 1 phage/100 bacteria, and the culture was allowed to incubate until the OD reached a minimum for 30 min. 10 ml of chloroform was added and allowed to shake for 10 min and was then centrifuged for 20

min at 6000 rpm in GSA rotor to remove cellular debris. The supernatant was collected and 1/10th volume of 5M NaCl and 1/10th w/v of polyethylene glycol was added to precipitate the phage, this was held at 4°C overnight. The phage were then pelleted by centrifugation at 6000 rpm in a GSA rotor at 4°C. The pellet was resuspended in phosphate buffered saline and CsCl was added to a density of 1.5 g/ml. The sample was spun in Ti80 (Beckman) rotor at 34,000 rpm overnight. The phage band was extracted with a syringe and was dialyzed against phosphate buffered saline (pH 7.4).

DNA Isolation and Sequencing

DNA was isolated from CsCl purified phage by phenol/chloroform extraction. The phage DNA was used directly as a template for DNA sequencing which was carried out by Commonwealth Biotechnologies in Richmond, VA . Both strands were sequenced (of the tail gene region of θ K1-5). DNA database searches were done by BLAST (1), and sequence alignments were performed with the Wisconsin Package (9).

Mutagenesis

Cesium purified phage were mutagenized with UV light using a model TM 36 chromatovue transilluminator (UVP, Inc.). Phage were typically exposed for 10-20 sec, which reduced viability by 1000 fold. The mutagenized phage were then amplified on ATCC 23503 or ATCC 23506 and subjected to selection and amplification as described above. Phage were also mutagenized by incubation with 400 mM hydroxylamine until the phage titer was reduced by 100 fold. They were then plated on a double lawn of ATCC 23503 and ATCC 23506. Turbid plaques were picked, replaques for isolation, and tested for growth against a collection of K1 and K5 *E. coli* strains.

REFERENCES

1. **Altschul, S. F., W., Gish, W., Miller, E. W., Myers, D. J., and Lipman.** 1990. Basic local alignment search tool. *J. Mol. Biol.* **215**(3): 403-410.
2. **Botstein, D.** 1980. A theory of modular evolution for bacteriophages. *Ann. NY Acad. Sci.* **354**: 484-490.
3. **Brown, J. E., J. F. Klement, and W. T. McAllister.** 1986. Sequences of three promoters for the bacteriophage SP6 RNA polymerase. *Nucleic Acids Res.* **(14)**8: 3521-3526.
4. **Campbell, A., and D. Botstein.** 1983. Evolution of the lambdoid phages. In *Lambda II*. Cold Spring Harbor Laboratory. 365-380.
5. **Chandry, P. S., S. C. Moore, J. D. Boyce, B. E. Davidson, and A. J. Hillier.** 1997. Analysis of the DNA sequence, gene expression, origin of replication, and modular structure of the *Lactococcus lactis* lytic bacteriophage sk1. *Mol. Microbiol.* **26**(1): 49-64.
10. **Clarke, B. R., F. Esumah, and I. S. Roberts.** 2000. Cloning, expression, and purification of the K5 capsular polysaccharide lyase (KfIA) from coliphage K5A: evidence for two distinct K5 lyase enzymes. *J. Bacteriol.* **182**(13): 3761-3766.
15. **Crawford, J.T. and E.B. Goldberg.** 1980. The function of the tail fibers in triggering baseplate expansion of bacteriophage T4. *J. Mol. Biol.* **139**: 679-690.
20. **Desiere, F., S. Lucchini, and H. Brussow.** 1998. Evolution of *Streptococcus thermophilus* bacteriophage genomes by modular exchanges followed by point mutations and small deletions and insertions. *Virology.* **241**(2): 345-356.
25. **Devereux, J., P. Haeberli, and O. Smithies.** 1984. A comprehensive set of sequence analysis programs for the VAX. *Nucleic Acids Res.* **12**(1): 387-395.
30. **Gross, R. J., T. Cheasty, and B. Rowe.** 1977. Isolation of bacteriophages specific for the K1 polysaccharide antigen of *E. coli*. *J. Clin. Microbiol.* **6**(6): 548-550.
- Gupta, D. S., B. Jann, G. Schmidt, J. R. Golecki, I. Ørskov, F. Ørskov, and K. Jann.** 1982. Coliphage K5, specific for *E. coli* exhibiting the capsular K5 antigen. *FEMS Microbiol. Lett.* **14**: 75-78.

12. Gupta, D. S., B. Jann, and K. Jann. 1983. Enzymatic degradation of the capsular K5-antigen of *E. coli* by coliphage K5. FEMS Microbiol. Lett. **16**: 13-17.
13. Haggård-Ljungquist, E., C. Halling, and R. Calendar. 1992. DNA sequences of the tail fiber genes of bacteriophage P2: evidence for horizontal transfer of the tail fiber genes among unrelated bacteriophages. J. Bacteriol. **174**(5): 1462-1477.
14. Hanfling, P., A. S. Shashkov, B. Jann, and K. Jann. 1996. Analysis of the enzymatic cleavage (beta elimination) of the capsular K5 polysaccharide of *E. coli* by the K5-specific coliphage: a reexamination. J. Bacteriol. **178**(15): 4747-4750.
15. Hendrix, R. W., M. C. M. Smith, R. N. Burns, M. E. Ford, and G. F. Hatfull. 1999. Evolutionary relationships among diverse bacteriophages and prophages: All the world's a phage. Proc. Natl. Acad. Sci., U.S.A. **96**: 2192-2197.
16. Israel, V. 1978. A model for the adsorption of phage P22 to *Salmonella typhimurium*. J. Gen. Virol. **40**: 669-673.
17. Jann, K., and B. Jann. 1987 Polysaccharide antigens of *E. coli*. Rev. Infect. Dis. **9**(5): S517-S526.
18. Jeng S.T., S.H. Lay, and H.M. Lai. 1997. Transcription termination by bacteriophage T3 and SP6 RNA polymerases at Rho-independent terminators. Can J. Microbiol. **43**(12): 1147-1156.
19. Juhala R. J., M. E. Ford, R. L. Duda, A. Youlton, G. F. Hatfull, and R. W. Hendrix. 2000. Genomic sequences of bacteriophages HK97 and HK022: Pervasive genetic mosaicism in the lambdoid bacteriophages. J. Mol. Biol. **299**(1): 27-51.
20. Long, G. S., J. M. Bryant, P. W. Taylor, and J. P. Luzio. 1995. Complete nucleotide sequence of the gene encoding bacteriophage E endosialidase: implications for K1E endosialidase structure and function. Biochem. J. **309**: 543-550.

21. Machida, Y., K. Miyake, K. Hattori, S. Yamamoto, M. Kawase, and S. Iijima. 2000. Structure and function of a novel coliphage-associated sialidase. FEMS Microbiol. Lett. **182(2)**: 333-337.
22. Monod, C., M. Repoil, F. Kutateladze, F. Tetart, and H. M. Krisch. 1997. The genome of the Pseudo T-even bacteriophages, a diverse group that resembles T4. J. Mol. Biol. **267**: 237-249.
23. Montag, D., H. Schwarz, and U. Henning. 1989. A component of the side tail fiber of *Escherichia coli* bacteriophage λ can functionally replace the receptor-recognizing part of a long tail fiber protein of unrelated bacteriophage T4. J. Bacteriol. **171(8)**: 4378-4384.
24. Montag, D., S. Hashemolhosseini, and U. Henning. 1990. Receptor recognizing proteins of T-even type bacteriophages. The receptor recognizing area of proteins 37 of phages T4 and Tu1a and Tu1b.
25. Neve, H., K. I. Zenz, F. Desiere, A. Koch, K. J. Heller and H. Brussow. 1998. Comparison of the lysogeny modules from the temperate *Streptococcus thermophilus* bacteriophages TP-J34 and Sfi21: implications for the modular theory of phage evolution. Virology, **241(1)**: 61-72.
26. Nimmich, W., G. Schmidt, and U. Krallmann-Wenzel. 1991. Two different *E. coli* capsular polysaccharide depolymerases each associated with one of the coliphage Φ K5 and Φ K20. FEMS Microbiol. Lett. **82**: 137-142.
27. Nimmich, W., U. Krallman-Wenzel, B. Muller, and G. Schmidt. 1992. Isolation and characterization of bacteriophages specific for capsular antigens K3, K7, K12, and K13 of *E. coli*. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. **276(2)**: 213-220.
28. Nimmich, W. 1994. Detection of *E. coli* K95 strains by bacteriophages. J. Clin. Microbiol. **32(11)**: 2843-2845.
29. Petter, J.G., and E. R. Vimr. 1993. Complete nucleotide sequence of the bacteriophage K1F tail gene encoding Endo-N-Acylneuraminidase (Endo-N) and comparison to an endo-N homolog in bacteriophage PK1E. J. Bacteriol. **175(14)**: 4354-4363.

30. Seckler, R. 1998. Folding and function of repetitive structure in the homotrimeric phage P22 tailspike protein. *J. Struct. Biol.* **122**: 216-222.
31. Schicklmaier, P., and H. Schmeiger. 1997. Sequence comparison of the genes for immunity, DNA replication, and cell lysis of the P22-related *Salmonella* phages ES18 and L. *Gene*. **195**: 93-100.
32. Silver, R. P., and E. R. Vimr. 1990. Polysialic acid capsule of *E. coli* K1. in *The Bacteria*, vol. 11. Molecular basis of bacterial pathogenesis. pp 39-60. Academic Press, Inc., New York.
33. Steven, A.C., B. L. Trus, J. V. Maizel, M. Unser, D. A. D. Parry, J. S. Wall, J. F. Hainfield, and W. F. Studier. 1988. Molecular substructure of a viral receptor-recognition protein. *J. Mol. Biol.* **200(2)**: 351-365.
34. Szybalski, W., and E. H. Szybalski. 1974. Visualization of the evolution of viral genomes. In *Viruses, evolution and cancer*. pp. 563-582. Academic Press, New York.
35. Tetart, F., F. Repoila, C. Monod, and H.M. Krisch. 1996. Bacteriophage T4 host range is expanded by duplications of a small domain of the tail fiber adhesion. *J. Mol. Biol.* **258(5)**: 726-731.
36. Tetart, F., C. Desplats, and H.M Krisch. 1998 Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesion specificity. *J. Mol. Biol.* **282(3)**: 543-556.
37. Tomlinson, S., and P. W. Taylor. 1985. Neuraminidase associated with coliphage E that specifically depolymerizes the *E. coli* K1 capsular polysaccharide. *J. Virol.* **55(2)**: 374-378.
38. Yin, J. 1993. Evolution of bacteriophage T7 in a growing plaque. *J. Bacteriol.* **175(5)**: 1272.

* * * * *

While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All figures, tables, and appendices, as well as patents, applications, and publications, referred to above, are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising a phage having multiple host specificity based on having multiple different host tail proteins and a pharmaceutically acceptable excipient.
- 5 2. A pharmaceutical composition according to claim 1, said phage having multiple different hydrolytic tail proteins.
- 10 3. A pharmaceutical composition according to claim 1, said phage having multiple different K specific hydrolytic tail proteins.
- 15 4. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of Φ K1-5 on deposit as ATCC Accession No. PTA-3495 irrespective of the tail gene region.
- 20 5. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of Φ K1-5 on deposit as ATCC Accession No. PTA-3495 including the tail gene region.
6. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of Φ K1E.
- 25 7. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of Φ K5.
8. A pharmaceutical composition according to claim 1, said phage comprising the full length genome of Φ K20.
- 30 9. A pharmaceutical composition according to claim 1, wherein said phage infects *Escherichia* and additionally infects a bacterium selected from the group consisting of *Escherichia*, *Shigella*, *Salmonella*, *Enterobacter*, *Yersinia*, *Vibrio*, *Legionella*, *Pseudomonas*, *Neisseria*, *Bordetella*, *Helicobacter*, *Listeria*, *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Clostridium*, *Corynebacterium*,

Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

5 10. A pharmaceutical composition according to claim 1, wherein said phage infects *Shigella* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia* and
10 *Klebsiella.*

11. A pharmaceutical composition according to claim 1, wherein said phage infects *Salmonella* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia* and *Klebsiella.*

20 12. A pharmaceutical composition according to claim 1, wherein said phage infects *Enterobacter* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia* and *Klebsiella.*

30 13. A pharmaceutical composition according to claim 1, wherein said phage infects *Yersinia* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium,*

Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

5 14. A pharmaceutical composition according to claim 1, wherein said phage infects *Vibrio* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and*
10 *Klebsiella.*

15 15. A pharmaceutical composition according to claim 1, wherein said phage infects *Legionella* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

20 16. A pharmaceutical composition according to claim 1, wherein said phage infects *Pseudomonas* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*
25

30 17. A pharmaceutical composition according to claim 1, wherein said phage infects *Neisseria* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium,*

Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

18. A pharmaceutical composition according to claim 1, wherein said phage
5 infects *Bordetella* and additionally infects a bacterium selected from the group
consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria,
Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,
Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus,
10 *Serratia and Klebsiella.*

19. A pharmaceutical composition according to claim 1, wherein said phage
infects *Helicobacter* and additionally infects a bacterium selected from the group
consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
15 *Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria,*
Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,
Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus,
Serratia and Klebsiella.

20. A pharmaceutical composition according to claim 1, wherein said phage
infects *Listeria* and additionally infects a bacterium selected from the group consisting
of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella,*
Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus,
Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium,
25 *Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and*
Klebsiella.

21. A pharmaceutical composition according to claim 1, wherein said phage
infects *Staphylococcus* and additionally infects a bacterium selected from the group
30 consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria,
Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,

Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

5 22. A pharmaceutical composition according to claim 1, wherein said phage infects *Streptococcus* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus,*
10 *Serratia and Klebsiella.*

23. A pharmaceutical composition according to claim 1, wherein said phage infects *Enterococcus* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
15 *Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

20 24. A pharmaceutical composition according to claim 1, wherein said phage infects *Clostridium* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,*
25 *Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

25. A pharmaceutical composition according to claim 1, wherein said phage infects *Corynebacterium* and additionally infects a bacterium selected from the group
30 consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,*

Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

26. A pharmaceutical composition according to claim 1, wherein said phage
5 infects *Mycobacterium* and additionally infects a bacterium selected from the group
consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria,
Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,
Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus,
10 *Serratia and Klebsiella.*

27. A pharmaceutical composition according to claim 1, wherein said phage
infects *Treponema* and additionally infects a bacterium selected from the group
consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
15 *Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria,*
Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,
Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus,
Serratia and Klebsiella.

28. A pharmaceutical composition according to claim 1, wherein said phage
infects *Borrelia* and additionally infects a bacterium selected from the group consisting
of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella,*
Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus,
Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium,
25 *Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and*
Klebsiella.

29. A pharmaceutical composition according to claim 1, wherein said phage
infects *Campylobacter* and additionally infects a bacterium selected from the group
30 consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria,
Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,

Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

5 30. A pharmaceutical composition according to claim 1, wherein said phage infects *Chlamydia* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus,*
10 *Serratia and Klebsiella.*

31. A pharmaceutical composition according to claim 1, wherein said phage infects *Haemophilus* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio,*
15 *Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

20 32. A pharmaceutical composition according to claim 1, wherein said phage infects *Serratia* and additionally infects a bacterium selected from the group consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium, Mycobacterium,*
25 *Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.*

33. A pharmaceutical composition according to claim 1, wherein said phage infects *Klebsiella* and additionally infects a bacterium selected from the group
30 consisting of *Escherichia, Shigella, Salmonella, Enterobacter, Yersinia, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Corynebacterium,*

Mycobacterium, Treponema, Borrelia, Campylobacter, Chlamydia, Haemophilus, Serratia and Klebsiella.

5 34. A pharmaceutical composition according to claim 1, said phage further having a gene encoding a factor that permits said phage to replicate and function in another type of bacteria generally not infected by said phage.

10 35. A pharmaceutical composition comprising a phage having mammalian host specificity by presenting on the tail of said phage a mammalian cell surface-receptor ligand, wherein the phage genome encodes a therapeutic gene product.

15 36. A pharmaceutical composition according to the preceding claim, wherein said therapeutic gene product is a protein cytocide, an antisense, a ribozyme, a dominant negative mutant, or a therapeutic protein.

20 37. A method of making a pharmaceutical composition comprising:
 (a) isolating a phage according to claim 1 wherein the acquisition of new tail genes occurs by recombination in nature; and
 (b) combining said phage with a pharmaceutically acceptable excipient.

25 38. A method of making a pharmaceutical composition comprising:
 (a) generating a phage according to claim 1 wherein the acquisition of new tail genes is generated by technology in the laboratory; and
 (b) combining said phage with a pharmaceutically acceptable excipient.

30 39. A method of preventing or treating bacterial infection comprising administering the pharmaceutical composition of any of claims 1-34 to an individual in need thereof to prevent or treat bacterial infection.

 40. Use of the pharmaceutical composition of any of claims 1-34 for the preparation of a medicament for prevention or treatment of bacterial infection.

1/4




FIG. 1




FIG. 2

3/4




FIG. 3A




FIG. 3B




FIG. 4

SEQUENCE LISTING

<110> THE GOVERNMENT OF THE UNITED STATES OF AMERICA,
AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF
HEALTH AND HUMAN SERVICES
MERRIL, CARL L.
ADHYA, SANKAR L.
SCHOLL, DEAN

<120> BACTERIOPHAGE HAVING MULTIPLE HOST RANGE

<130> NIH205.001VPC

<140> unknown

<141>

<150> US 60/220,987

<151> 2000-07-25

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 5518

<212> DNA

<213> Bacteriophage k1-5

<400> 1

```

ggtaggtcctt ggtgtagacc ttggctcttg cacggaatcc tctgtgacag atgtggctctg 60
ccaagtgate acctgtgaat aagtttctag aagttctggc aggtcttatt ggctgcttg 120
tctctgctaa gaagaaacaa gaagagaagg aggcacaaag tgaagcgaat catgttagtg 180
acaacccttc tgattggttc gctgaccact tccgggtgtc agcaggcgtt accagagaaa 240
gcaatggtga aacctctgag gccgacgctg acggcagttt acgaggtaga cgataaggtc 300
tgctttagta agcctgacgc taaaaaactt ggtttgtaca ttctctcgct agaacgcgga 360
tacaattaat acatagcttt atgtatcagt gtcttacgat ttactggaca ctatagaaga 420
ggtaagatag cgccgttctt ttgagcggcc tattactagc caatcttcat agggaggggtt 480
ggaaagtaat aggagatagc atggctaaat taaccaaacc taatactgaa ggaatcttgc 540
ataaaggaca atctttgtat gagtaccttg atgcgagagt tttaacatca aagccgtttg 600
gtgctgcagg tgacgccact actgatgata cggagggtat agctgcttca ttaaactctc 660
agaaagctgt cacagtctca gatggtgtat tctctagctc tggtattaac agtaattact 720
gtaacttaga cggcaggggt agtggcgtgc taagtcaccg ttcaagtaca ggtaactact 780
tagtatttaa caatctacgt gcaggctcgt taagtaatat tacggtagaa agtaataagg 840
cgactgatac aactcagga cagcagggtat cccttgctgg tggaagtgat gttactgtaa 900
gtgacgttaa cttctcaaac gttaaaggta ctggtttcag tttaatcgca taccctaata 960
atgcgccacc tgatggactt atgattaaag gcattcgagg tagctattcc ggctatgcta 1020
ctaataaggc agccggatgc gtacttgctg attcctcagt taactccctc atagataacg 1080
tcattgctaa gaactaccct cagttcggag cagtagagtt gaaaggtaga gccagttaca 1140
acatagtcag taatgttata gggacagatt gccagcatgt aacttacaac ggactgaag 1200
ggccaatagc tccttctaata aaccttatca agggggtgat ggctaataac cctaagtatg 1260
cagcggttgt tgcaggcaaa ggaagtacga acttaatctc agacgtgctc gtagattact 1320
caacttctga tgctaggcag gctcatggtg ttacagtaga gggttctgat aacgtcataa 1380
ataatgtgct tatgtcagga tgtgatgga ctaactcttt aggacaaggg cagactgcta 1440
caattgcacg ctttatagg acagctaata acaactatgc gtctgtattt cctagctaca 1500
gtgctacagg tgttattact ttcgaatccg gctctacccg taacttcgta gaggtaaagc 1560
accctggcag gagaaacgac cttctcagtt ctgctagtac tattgacggg gcagctacta 1620

```

ttgacggcac	tagtaatagt	aaegttagtgc	acgcacctgc	cttagggcag	tacataggtg	1680
gtatgtcagg	taggttcgaa	tggcgggatta	agtcacatgtc	actcccttca	ggcggttctta	1740
cttctgctga	taagtacaga	atgcttggag	atgggtgctgt	gtcattagct	gtaggtgggg	1800
gcacttcttc	tcaagtctgc	ctatttactt	ctgatggtag	ttctcggaca	gtgtccctca	1860
ccaacggtaa	cgtgcgtctt	tctaccagta	gcacaggctt	tttgcagtta	gggtgctgatg	1920
caatgacccc	agacagtact	ggtagacatac	catttaggttc	cgccagccga	gcatgggtctg	1980
gcggttttac	tcaagcagca	ttcactgtta	cctcagatgc	tcgggtgtaaa	acagaacctc	2040
ttactatctc	agatgcctta	ctggatgctt	gggtctgaagt	tgactttgtg	cagtttcagt	2100
atttgatcg	tgttgaggag	aagggtgcag	actcagctag	atggcacttc	ggatatcatcg	2160
ctcagcgagc	taaggaggct	ttcgaacgtc	acggtataga	tgcacatcgc	tatggcttct	2220
tgtgcttcca	cagttgggag	gatgtatac	aggaagatgc	caatggctct	cgtaaactga	2280
ttacaccagc	agggtcccgc	tacgggtattc	gttacgagga	agtactgata	ttagaggctg	2340
cgttgatgcg	gcggtactatt	aagcgtatgc	aggaagcact	agcttccctg	cctaagtaag	2400
caacaggcag	tgcgtaaagca	ctgcttttag	cgcaactttt	cttaaagggtt	atcacgggtgg	2460
tagcctttca	gaaaaggagg	ttacatgatt	caaagactag	gttcttcatt	agttaaattc	2520
aagagtaaaa	tagcaggtgc	aatctggcgt	aacttggatg	acaagctcac	cgaggttgta	2580
tcgcttaaa	attttggagc	caaagggtgat	ggtaagacaa	acgaccaaga	tgcagtaaat	2640
gcagegatgg	cttcaggtaa	gagaattgac	gggtgctgggtg	ctacttacaa	agtatcatct	2700
ttacctgata	tggagcgatt	ctataacacc	cgttctgtag	gggaacgttt	agcagggtcaa	2760
cctctttact	atgtgagtaa	agggttttatc	aatgggtgaac	tatataaaat	cacggataac	2820
cctttattaca	atgcttggcc	tcaagacaaa	cgttttgtat	atgagaacgt	gatatattgca	2880
ccttacatgg	gtagtgcacg	tcattgggtt	agtcgtctgc	atgtatcatg	ggttaagtct	2940
gggtgacgatg	gtcaaacatg	gtctactcca	gagtgggttaa	ctgatctgca	tccagattac	3000
cctacagtga	actatcattg	tatgagtatg	gggtgatgtc	gcaaccgtct	gtttgccatg	3060
attgaaacac	gtactttagc	caagaacaaa	ctaaccaatt	gtgcattgtg	ggatcgccct	3120
atgtctcgta	gtctgcatct	tactgggtgg	atcactaagg	ctgcaaatac	gcaatatgca	3180
acaatacatg	taccagatca	cggactattc	gtgggctgatt	ttgttaactt	ctctaattct	3240
gcggttaacag	gtgtatcagg	tgatatgact	gttgcaacgg	taatagataa	ggacaacttc	3300
acgggttctta	cacctaacca	gcagacttca	gatttgaata	acgctggaaa	gagttggcag	3360
atgggtactct	ctttccataa	gtctccatgg	cgttaagacag	atcttgggtct	aatccctagt	3420
gtcacagagg	tgcatagctt	tgctactatt	gataacaatg	gctttgttat	gggctatcat	3480
caagggtgatg	tagctccacg	agaagttgg	cttttctact	tccctgatgc	tttcaatagc	3540
ccatctaatt	atgttcgtcg	tcagatacca	tctgagtatg	aaccagatgc	gtcagagcca	3600
tgcataaagt	actatgacgg	tgtattatac	cttatcactc	gtggcactct	tggtgacaga	3660
cttggaagct	ctttgcatcg	tagtagagat	ataggtcaga	cttgggagtc	actgagattt	3720
ccacataatg	ttcatcatac	taccctacct	tttgctaaag	taggagatga	ccttattatg	3780
tttggttcag	aacgtgcaga	aatgaattgg	gaagcagggtg	caccagatga	tcgttacaag	3840
gcatcttatac	ctctgacctt	ctatgcacga	ttgaatgtaa	acaattggaa	tcagatgat	3900
attgaatggg	ttaacatcac	agaccaaatc	tatcaagggtg	acattgtgaa	ctctagtgtg	3960
gggtgtaggtt	cggtagtagt	taaagacagc	tacatttact	atatcttttg	tggcgaaaac	4020
catttcaacc	caatgactta	tgggtgacaac	aaagggtaaag	acccatttaa	aggtcatgga	4080
cacctactg	atatatactg	ctataagatg	cagattgcaa	atgacaatcg	tgtatctcgt	4140
aagtttacat	atgggtgcaac	tccgggtcaa	gctataccta	ctttcatggg	tactgatgga	4200
atacgaataa	tccctgcacc	tttgtagttt	tcagataaca	ttgttacaga	ggatactaaa	4260
gttggacact	taacacttaa	agcaagcaca	agttccaata	tacgatctga	agtgcatatg	4320
gaagggtgaat	atggctttat	tggcaagtct	gttccaaagg	acaacccaac	tggtcaacgt	4380
ttgattatctt	gtgggtggaga	agagacttgc	tcctcttcag	gtgcacagat	aactttgcac	4440
ggctctaatt	caagtaaggc	taatcgtatc	acttataacg	gaaatgagca	cctattccaa	4500
gggtgcaccaa	tcattgctgc	tgtagataac	cagtttgctg	ctgggtggacc	tagtaaccga	4560
ttcactacca	tctacctagg	tagtgaccct	gttacaactt	cagatgctga	ccacaagtac	4620
agtatctcta	gtattaatac	caagggtgta	aaggcttgga	gcagggttgg	ttttaaacag	4680
tatgggttga	atagtgaagc	agagagggac	cttgatagca	tacacttcgg	tgtcttggct	4740
caggatattg	tagctgcttt	tgaagctgaa	gggttggtatg	ccattaagta	tgggaattgtg	4800
tccttcgaag	aaggtaggta	cgggtgtgag	tatagtgaag	ttctaatact	agaggctgct	4860
tatactcgtt	atcgtttaga	caagtttagag	gagatgtatg	ccactaataa	aatcagttaa	4920
gcaagctgct	tactccaga	acacagaaga	gcttattcaa	tcaggacgtg	accctaagca	4980
ggcttatgcc	attgccaaag	atgttcaacg	tcgtgccatg	aagaaacctt	ctgcatcttc	5040
tgcgtaagca	ggttaatatc	ttagtataaa	caagggcaga	cttaggtttg	tccttagtgt	5100

```

attccaaagg aggtaacatg ctgaaagatg gttgggttct atatgaccct acagacccta 5160
agaattggct acaggttatc gctatagctt gtgcaggtag cctattggct gccctgatgt 5220
attcattatg gatgtacaca aagtaaccaa agtcaaaatt ttgatgtagg cgtgtgtcag 5280
ctctctcgcc ctgcgcctcg ccgggttgtc cccatagggt ggccctgaggg aatccgtctt 5340
cgacgggagc ggctgatgta ctcccttgtc agtacaaggg aggcggaggg aacgcctagg 5400
gaggcctagg aatggcttag tgggtggaca ggtgattacc ttagtgaagc ctcttagtgc 5460
attcctgagg ccattcaggg cgtttatgag ggattgacag ggtgtgaggg cgtgggct 5518

```

<210> 2

<211> 2211

<212> DNA

<213> Salmonella phage Sp6

<220>

<221> misc_feature

<222> (1)...(2211)

<223> n = A,T,C or G

<400> 2

```

aagttttcca attaatacat aaccttatgt atcatacaca tacgatttag gtgacactat 60
agaatagaag tatagtgccg ttcttttgag cggcctatta ctccaccagtc ttcacgggga 120
gggctggata gtaataggag gtttatgtca ttaactaaac cacgttgctt caggaaggca 180
agttatctaa gccagttagg cactttgcag aatctggcta aacttgagga tgacgtactt 240
gttatcgatg ttgactacaa gttcaccaat ggagagactg tagacttcaa aggtcgattg 300
gttcgtatag aatgcgaagc tagattcata ggcgatggag ctttaatttt cactaatatc 360
gctagtgggt ctgtagtaga aaagcctttc atggagagca agtccacacc ttgggttacc 420
tacccttggg cagaagatgg caagtggatt acagatgcac aagctgttgc tgctacgctt 480
aaacaatcta agaccgaagg atatcaacct ggagtcaatg attgggtcaa gttcccagga 540
cttgaagcat tgataccgca agaggtgaaa gaccagtatg tagtatcaac actggacatc 600
cgtgattgtg taggtgttga ggtagacgt gctgggtggc ttatggcagc ttacttggtc 660
cgcaactgtc atcattgtaa ggtaattgat tctgacacca tcattgggtg taaagacggc 720
atcataacct ttgaaaactt aggtgggtgaa tgggggtatc gcaactatgc cataggtggg 780
cgtgtacatt atggctcatg tagtgggtg cagtttcttc ggaacaatgg aggtgcatca 840
cataatgggt gagttattgg tgtgacctca tggcgcgagc gtgagtctgg gtttaaaaca 900
tggcaagggt ctgtaggtgc aggtacatct cgtaactata accttcagtt cegtgactca 960
gttgcatatt ctccagtatg ggacggcttt gacttaggct cagaccctgg aatggcacca 1020
gaagaggata gaccgggaga ttacctgta tctcaatacc ccatgcacca gttacctaat 1080
aaccacatgg ttgataacat acttgttatg aactcattag gtgtagggtt aggtatggac 1140
ggtagagggt gttatgtgtc gaattgtacc gtgcaggatt gtgcaggcgc aggtatactt 1200
gctcatgcat tcaaccgtac ctctctaac attacggtga ttgactgcaa ctacatgaac 1260
ttcgattcag accagataat catcattggg cactgcatcg tgaatggcat ccgagcagcg 1320
ggtattaagc ctccagccatc caaaggcatg atcatcagtg cacctcactc aaccttgagc 1380
ggtattgtgg gtaatgtgcc gccagaccgt attccttgag gtaacatcct tgaccctgtg 1440
ttgggtcata caaggattaa tgggtttaat agtgactcgg cggaactgag cttcagaatc 1500
cacaagctta ccaagacctt ggatagtggt gctattcgct ctacgctgaa cgggtgggccg 1560
ggtactgggt ctgcatggac tgagatgact gcaatttcag ggtcagctcc aaatgctgtc 1620
tcgttgaaga ttaaccgagg agacttcaag gcaactgaga taccagtagc acctactgtg 1680
cttccagatg aagcggtaag agaccacagc tctatcgcac tttattttga tcaggaagct 1740
ctttgggctt tagttaagaa gccgaacgga agcctcacac gaatgaagct tgcttaatgt 1800
aggcagcgcg ttagecgtgc tttcacgoga acttttctta aaggttatca tagtggtagc 1860
ctttcagaaa aggaggtgac atgatacaaa gattagggtc ttccttagtg aagatgcaa 1920
atggtattac attgacacag tgggtgcaac ctgcaaacat catcaaggta gatgatgcac 1980
catacaatgg agaccttatt gctgcatata atgctattcc cgttataggt aattatgctt 2040
tggttcttac caaccacact tacaatgcag ttgggttgtt tgatgcaggt ccgtaacatg 2100
aagcctaaca tcaccatcat tgggtgctgg atgcctcaac ttgcagatga taggtcgtcc 2160
tttgttgaaa gntctggcac tatcattaaa ggcgcaatca agaacttccg c 2211

```

<210> 3
 <211> 9643
 <212> DNA
 <213> Bacteriophage K1-5

<220>
 <221> misc_feature
 <222> (1)...(9643)
 <223> n = A,T,C or G

<400> 3
 ttcgtcgctg cggtagcctg atgtgtacct taggttattc cttgatggat agcttaggtt 60
 agccttagtg gattacctta gttaaagcct tagtgcttca cttagtatca gcttagtagt 120
 gtaccttagt aagtcttagt gtcttctctt agtgattgca catgcnagca tgtaagatgc 180
 taataggtcg cggtcggcag accgctaaag aaagagaatg gtaataagat gcagtaggag 240
 gaacaccaga agcctagcca acctaagcta tcctagctct atatctattg cttttcctta 300
 gtctaacacg ttagacaacc tatcttattc ttagtgatgg taacttagtg ttgacaagat 360
 aatcttagtg taatactatg catcacgtag gcggtgctga ggcacctagt agccagctag 420
 taaggcatac gaagagacta gcgcttacat tgctctttaa caatttgctt agtgtaacct 480
 atgtatgccg tggttaacta cttattgaat gaggtattaa ctatgacatt aaataaccgt 540
 gaactgtccg ttctcttcac tctgttgtgc tacatgattc gtaacaacga attacttaca 600
 gatgatgagt tagccttgta tcaccgcttt cttaacgaag gttggaccga tacagttaat 660
 caataccgta acatgataga tgagttgagg gagggtaaat aatgtatcaa catgaggtat 720
 tctttgaatc agctagcgaa gctattcgct tccgtgatga tatgatgcaa gctgggtgtag 780
 gcggtgatgt gtatcactat ttgatagatt acgacactga atatcaccga gttaccttag 840
 tatctgagta tgacaaccaa gtcattactg agtatctagg cagtgaagat tacgattacg 900
 atgaagtaat cagcacaat ctctaaatta actgttgaca gccacggcat acaaggttac 960
 attaaagcat aagacggcga cgtctttaa catcccgtc ttaacaata cggtttgtgt 1020
 cttgataggc taactaacta actaaggtaa ttatcatgaa agggttaatt tgtgtagaac 1080
 gtatgggtcaa tggtaaaactt gaaatattac cactggaaaa ccaatctagc ttcaaagagt 1140
 ggtatggctg tttctcactg atttaaggta aaggctggca ctagtacagg tatcaaggcg 1200
 caaaccaagc tctttaacaa tttggatggg agcttcttag tctggatagg ttaaacctag 1260
 gagattctct tgagtctcct ataatgtaac ctaactaact aaatgaggat taaatcatgg 1320
 aacgcaatgc taacgcttac tacaaccttc tggctgcaac tgttgaagca ttcaacgagc 1380
 gtattcagtt tgatgagatt cgcgaaagggt atgattactc tgatgcacta catgaggttg 1440
 tagacagcaa tgttccagtt tattacagcg aaatctttac agtgatggct gctgatggta 1500
 ttgatgttga ttttgaggat gctggtttga ttcttgacac gaaggatgta accaagattc 1560
 tacaagctcg catcttgaa gctctttata atgatgtacc aaatgacagc gatgtagttt 1620
 ggtgtgaagg cgaagaagag gaagaataag gatggaaaag caatataact ttatcttttc 1680
 agacggtgta accctgaagt gttccctacg attcgcacaa attcgtgagg aagtactagg 1740
 cactacatac aaactattta gctgacacta taagagaagg cttacaagg cgttactaag 1800
 gtagcgctg attaaacttt cacttactag gagttgagat tatgaaaacc ttgattggat 1860
 gcttcttggt ggcttctctt gctctggcat ttaccgctaa agctgggtat gacgcttata 1920
 aagtagaaca agcccagcaa gactgggcca aaaaaaggtt caacttggtg agcaagagca 1980
 acacctcaga gtactgcaac aaaacactaa gacacttatg gaaagagtaa ctagcctata 2040
 gccacctga gtgggctatg tgatatttac ttaacactat ataaggatgat tactatgact 2100
 actgaaaaca ccctcgtgtc tgtccgtgaa gctgcaaccg ctgaaatcaa gcaacattta 2160
 gacaatatcg gcacttctta catcaaagta ggggcttgct tgaatgagtt acgcggagac 2220
 tttgaagggtc aaaaagagtt tttagcctat gttgaagcag agtttgccat taagaaggca 2280
 caatgttaca agctgatgag ttagcccggt gtctttgaag gcgatgatcg ctttaaaggc 2340
 gtggcgatgc gtgtaatgct ggcgcttggt cctttcgctg atgaaaatat aatcatggag 2400
 aaggccgcag aactcgccgc aaatggcaag ctggacacta atgccgtaaa cgccctgatt 2460
 gaacctaaag aagagtcaaa ggccgaaacg gtacaatcta aggctgagac agtaaaaccg 2520
 caggagaagc cgactgagtc cgcagaatca catgaaatgc aagcgccgca ggtagtgcc 2580
 ccgcgagcg agcaggagtc cgacgaatca gcaacttggg aagaggaaaag caaacgggaa 2640
 gcgccaaggc cagctccgat ggataacacg gctaatactg agaatgccgc tattgctggt 2700
 ctgctggcac aaattaaagc actgactgag caattacagg cagccaatga ccgcatcgcc 2760

```

tccttaagta ggcacgcga aagcaagaag gcatccgcac ctatgctgcc gcagttcaaa 2820
tcttcctgct tctacgctcg cttaggcttg agcgcgagg aggcaacgaa gaaaacagca 2880
gttaacaagg cagcgccgga actgggtaag ctgggatacg gtgaaggcca tgaggcatgg 2940
cccttaatct ctgaggcagt agaagagttg actaagtaac cttatcggtg gcattcttctt 3000
aggtgtcacc tattaagggtt tctttcacta ggagtaaaca agatgcaagg cctacacgct 3060
attcaacttc aacttgaaga agaaatgttt aacggcggtt tccgtcgctt tgaagcggac 3120
caacaacgcc agattgcatc cggtaatgaa tcagacacgg catggaatcg ccgcttattg 3180
tccgagttaa tgcgcgcaat ggctgaagggt attcaggcat acaaggaaga gtatgaagggt 3240
aaaagaggcc gtgcaccgcg tgcattagct ttcatttaact gcgtagaaaa cgaagtggca 3300
gcatatatca cgatgaaaat cgttatggat atgctgaaca cggatgtaac cttgcaggct 3360
atagccatga atgtagctga ccgcattgag gaccaagtac gttttagcaa gctggaagggt 3420
cagcgccgca aatactttga aaaagttaag aagtcactta aggcaagtaa gactaaatca 3480
tatcgccatg cgcacaacgt agcggtagtg gctgagaagt cagtagctga ccgtgacgct 3540
gattttctccc gctgggaggc atggcctaaa gacaccttgc tgcaaatgg gatgaccttg 3600
cttgaaatct tagagaatag cgtattcttc aacgggcaac ctgtcttcct ccgcaccttg 3660
cgcactaatg gcggcacaaca tgggtgtttac tacctacaga ctagtgaaca cgtagggtgag 3720
tggtataactg cattcaaaaga gcacgtagcg caactgagtc ctgcctatgc tccttgcgtc 3780
atccctccgc gtccgtgggt atcacctttt aacggcggtt tccacactga gaaagtagca 3840
agcccgatatt cgtctggtaa aaggaaaccg cgaacacgtc cgcaagctga ccaaaaagca 3900
aatgccagag gtttacaagg ctgttaacgc gttgcaggcg actaaatggc aggttaacaa 3960
ggaagtttta caggttggtg aagacgtcat ccgtctagac ctagggttatg gtgtaccttc 4020
ctttaaacca ctcatgacc gcgagaacaa gccagctaat ccagtgccgc tagaatttca 4080
gcacctacgg ggccgtgaac tgaaagaaat gcttacgccg gaacaatgcc aagcctttat 4140
caactggaaa ggtgaatgta ctaagctgta caccgctgaa actaagcgcg gaagcaaatc 4200
ggcggcaacc gttcgcatgg ttggtcaggc ccgtaaatat agccagttcg acgcaatcta 4260
cttcgtgtat gcaactggga gcccagccg cgtctacgcg caatctagca cactctcacc 4320
gcaatcaaat gacttgggca aggccttgct ccgttttacc gaaggcgagc gtcttgatag 4380
cgctgaggcg cttaaagtggt ttttgggtgaa cggggctaat gatagtgaat ttcaagacat gtgccgcgac 4440
aacttttgac gtgcgcaccg ctacgtgctg gatagtgaat ttcaagacat gtgccgcgac 4500
attgcagcgg atccgctgac cttcactcaa tgggtaaatg ccgactcccc ttacggcttc 4560
cttgcatggt gctttgaata tgcgcgttat ctggatgcac tggatgaagg cacgcaagac 4620
caattcatga cgcacctccc agtccatcaa gatggtagtt gttctgggtat ccagcactac 4680
agtgcctatgc tacgcgatgc agtaggtgcg aaagcagtaa accttaagcc ctctgactct 4740
cctcaagata tttatggtgc cgttgccgag gtagtaattc agaagaatta tgcatacatg 4800
aatgcagagg atgcggaaac cttcacttct ggcagcgtga ctttaacagg tgcggagctg 4860
cgtagtatgg ctagtgcgtg ggatatgata ggaatcactc gcggcctgac caaaaagccc 4920
gtaatgacac taccttatgg cagcacacgt ctaacctgcc gtgagtcagt gattgattat 4980
atcgttgatt tagaagaaaa agaggcccaa cgggctattg cgggaaggcc taaccgcaat 5040
cctgtacacc cttttgataa tgaccgtaaa gacagcctga cacctagggt agcttataac 5100
tatatgacag ctttaattctg gccttctatt tcggaagtgg ttaaagccct ttatagtggca 5160
atgaaaatga ttcgctcagct tgcccgtttc gcagctaaaa ggaatgaagg cttagagtat 5220
accctgccta ctggettcat cttgcaacaa aagattatgg ctactgatat cctccgcgta 5280
tctacttgct tgatgggaga aatcaagatg agtctacaga ttgaaacaga cgtagtggat 5340
gaaacggcaa tgatgggccc tgctgctcct aactttgtgc atggtcatga tggcagccac 5400
cttatcttaa cagtcctgcga ccttggtgat aaagggatta catctatcct agttattcat 5460
gactcttttg gcactcatgc aggcggtaca gccgaccttc gtgatatggt aagggcagaa 5520
atggtgaaga tgtatcaagg ccgtaatgca ctgcaaagcc tgctagatga gacgaagaa 5580
cgctgggttag ttgataccgg aatacaagta ccagagcaag gggagcttca ctttaacgaa 5640
atcttagttt cagactattg cttcgcataa tattaatagg ccattccttc gggagtggcc 5700
tttctttttac ctactacctg taacatttca ttaacataaa agtgtctcct atgtgagact 5760
tatttaccgg acactatagg atagccgtcg gagacgggaa agaaagggaa gataaaggat 5820
ataaaggaag taatagggtat taaaggttat ataggttatc taggaataac tattaccttc 5880
ttccttcttc ttattaccac tcagaggag ggcagacctt ggttgcttca catgtgagac 5940
ttcgttattha ccggacagta tagataagat taactcactt tggagattta accatgcgca 6000
acttttagaa gatggccggt aaagctaacc gttttgacat ggaagagggg cagaagaaag 6060
gcaagaagct gaataagcct gtccgtgacc gtgcatctaa acgcgctgcg tgggagttct 6120
aagttatggc tattattcag aatgtaccgt gtccctgctg tcaaaagaat ggacatgata 6180
ttactggcaa ccatctcatg atatttgatg atggtgccgg ctactgtaac cgtggacact 6240

```

ttcatgataa	tggtagacct	tactatcaca	agccggaagg	tggcatcgag	ataaccgagt	6300
tatctattac	tggcaatatc	aaatatacac	cttctcaatt	caaagaaatg	gagaaggaag	6360
ggaagataag	cgaccctaaa	ttacgtgcca	tcgcacttgg	tggatatgct	atgaaagacc	6420
gttgggaggt	catgaatgaa	caagaaaggg	cagagcaaga	agcagagtgg	aaacttgatg	6480
ttgaatgggt	cctcacgctt	aagcgtaaga	accttgtttc	caggcacatt	cgcggcgaca	6540
tttgcgcat	gtatgatgta	cgtgttgggc	acgatgaaga	gggtagagtc	tcacggcatt	6600
actatccgcy	cttcgaaaaa	ggtgagctag	taggcgctaa	gtgtcgcaca	ttacctaaag	6660
attttaagtt	tggtcattta	ggtaaactct	ttggtatgca	agatcttttc	ggtatgaata	6720
ctttgtctca	cgtgttagac	aaggaagac	gaaaggattg	cttgctcatt	gtcggcgccg	6780
aactggatgc	actagcagcg	cagcagatgc	tccttgattc	tgccaagggt	actaagtggg	6840
aaggccagcc	ataccatgta	tggctctgtca	acaaaggcga	gtcttgccct	gaagagatag	6900
tgcagaaccg	tgagcatatc	gcccaattca	agaagattat	atgggggttt	gatggagatg	6960
aggtagggca	gaagcagaat	cagcaagcgg	ctcgccgtgt	tcctggtaaa	tcctatatcc	7020
ttgaataccc	ctctggttgc	aaagatgcta	acaaggcatt	gatggctggc	aaggctaaag	7080
aatttgtaga	tgcatggttt	aatgccaaat	catctgatga	agtcttttgt	agccagatta	7140
aatctatcgc	atctcaaagg	gataagctca	aggctgcacg	tccagagcaa	ggactgtcat	7200
ggccttggcc	taagctgaac	aaggtaacgc	taggtattcg	taagaaccag	cttatcattg	7260
taggtgcagg	gtctggtgta	ggtaagactg	agttccttcg	tgaagtagtt	aagcacctca	7320
ttgaagaaca	cgggtaactc	gtaggcatca	tttctacaga	agaccgatg	gtcaaggtgt	7380
cccggtcttt	tatcggcaag	tggattgata	agcgtattga	gttacctcca	accaacgcac	7440
cgaaagaaga	cggataccgt	gaggtgttcg	actataccga	ggaagaagct	aacgccgcca	7500
ttgattatgt	agctgatata	ggtaagctgt	ttgtagctga	cctagagggt	gactattcga	7560
tggaaaaggt	agagcaaact	tgcttagagt	ttgaggctat	gggtatttct	aatatcatca	7620
ttgataaact	aacggggatt	aaattagatg	agcgtgcttt	tgggtgggaag	gttgggtgcac	7680
ttgatgaatg	cgtcaagcgg	attggtacta	tcaaagaccg	acaccgggtt	actatatcc	7740
ttgtatcaca	ccttacacgt	cctccggcaa	accgtaccca	acacgaagaa	ggtggcgaag	7800
ttatcctttc	tgacttcgga	ggctcaggcg	ctatcggatt	ctgggcatct	tacgccttgg	7860
ggattgagcg	taatacaaga	gctgaaacgc	ttgacgaaag	gactaccacg	tacatctcat	7920
gtgtcaaaga	ccgcgaccaa	ggatatctaca	ctggaaccaa	ggtcatgctt	aagggtgaca	7980
ttcaaaccgg	acgtttaatg	gaaccacaag	cccgacttaa	gtcatttgat	acagggtgaag	8040
caaggcaaca	agaagtacca	gattttaccg	atactataga	agagactacc	ttcgatgaag	8100
aaagtgagtt	ctgattagtg	tattttatcag	gcttgtctca	catgtgagac	aggctcttat	8160
taagtacatt	aaataactgg	agattgatta	tgtataactt	agtgttgaat	gtaggtgact	8220
ttgtacgcaa	catcaagaaa	gattcaagtc	gctatctttg	ccgtgggtgt	gtaacctttg	8280
taggtgagaa	cctgtattat	gtagaatata	gcagtgggtg	taagcaatat	taccacaaga	8340
agacagcaca	taaatatctt	gaaaagattg	tagagataaa	caatcaatgt	aagtgcatac	8400
atgatgaggt	ttgcgataaa	tgtgctcgcc	agatgcttaa	gaatttccta	gtcctctctt	8460
attatgggtgc	tggctcctcaa	acactagcag	agtgcatggc	agaaaagaaa	accacactca	8520
agaaagagcg	tcgcaatgta	atcactggta	agactcaaag	tgagatgatt	aagcaatgtg	8580
gcactgcatt	aggtgttaca	cagtttaata	ctcgtgcatt	gggtaaatcc	acaggacaag	8640
ctatggtaaa	gattggagaa	gccatgatgc	atccaaatgt	acctgtgcga	atcatggatg	8700
ttgaccatgc	aatcacagaa	caaggtacgc	aacgacgtgt	aattaataag	cattttgccg	8760
acactataga	aggcattatt	cgtaagcaag	ggttgaaagg	tcttcacatc	ttaaatggtg	8820
aagaattact	gtacctacct	atcgttactg	aagaaacata	cgtgaatatc	taaggagtta	8880
atcatgacta	aggtattaat	ttatatgcgt	ggacctcata	aatgctatgc	agttgtagca	8940
ccaaatggtg	ttaagcctta	tcgtacttca	aaaagattgg	cattaatagg	tgctagtagt	9000
agtgcgaagt	tccaaatgga	acttttttgt	cattggactg	aaaggcaatt	ccgtgaggat	9060
tttaaagtca	ttggcagctt	catggtgaaa	tatgcagaat	aaacatagtc	ttagaatggt	9120
cgatgggtcat	gaaaacctgc	aagccaagat	tactaaccaa	gccttcctgt	tcgcacagtt	9180
aactatggct	gaggctaaga	agaatagtct	cactcgtgaa	cagggttatca	aggaggccac	9240
ttgggaacca	caccaaggta	aatatatggg	ccacaaatta	actgtaacac	gcagtcgata	9300
agtcaagggt	tgtccaacgt	gttggacagc	ctttcatcat	attgattggg	aggtattaaa	9360
tgactaagtt	tactatgcaa	gacctcatta	aattacgtga	tgaaatagaa	tcaccggaag	9420
ttaatacaga	gtttcactac	attgatccac	gagataaacg	agagattcct	gattatcaga	9480
ttgagacgga	gttaattgat	gaagattatt	gattggaaga	aggaagcaga	aggccgtatc	9540
ctagnatggt	atgcggaggc	taaaggcctg	ctgggtgcta	tccgctacgg	tcacgtgaa	9600

gatgtacaca ttatttgctg catggacttg ctcaccactg agg

9643

<210> 4

<211> 14226

<212> DNA

<213> Bacteriophage K1-5

<220>

<221> misc_feature

<222> (1)...(14226)

<223> n = A,T,C or G

<400> 4

```
gcacaagagc ctatgccagn ttaaccaact gccaaagata ttggtaaatt tggactagct 60
aacttccctca tgtcttctgc ttttngcttc tggtgagaat ctgccttcta acttcgagat 120
taactatcga ggtaatatgc aacaattcta tgacaagcta gctatggatg agaataaaga 180
taaagttggc ttttaataagg caactggaac ctttactcca tataaagacg ctcacgggta 240
gtctatcggg tacggtcatt tcttaacgga agaagagaag cgaaacgggt atattaagat 300
tggcgatgaa ctagttccct atcgagggtc tatgtctcag cttacagaga gcaaggctcg 360
cgctcttatg gagcaagatg ctaagaagca tgtgcctcct actcgtgact ggaagattcc 420
gtttgaccag atgcaccctg cacagcaacg tggcttgatg gatttaagct acaatttagg 480
taaaggtgga atccagaact caccgcgtgc tcttgctgca ttcaaagctg gtaagcttac 540
ggagggcttt atcgaaatgc tgggcaactgc atcaagtga ggtaaagcgt ttcctggcct 600
actgaagcga cgcgctgagg catacaatat ggcatctgct ggtgggtgtgc ctaagattac 660
cgaagtggag actcgtgaag atggctccat gtgggttagg tttgggtggac ctatgccagc 720
aggttctgtc tcggcatgga ctcataaacg tattggcgcg gatgggttgg atcaggttta 780
tgaggctgca cctaccaagt tagctaaaga ttctaaggta ggtaaagtta agttgtagta 840
cctaactcaa ggcttgtctc acatgtgaga caggctctta tgataggcac tatggaggaa 900
ttatggaaca agacattaag actaattggg ctggatatgt ccagtctact cctgagccgt 960
tttctattga ggcggtccg gtatcggtc ctacgatacg ccagcgtaat gagttacaag 1020
agcaagttct tgaagctaaa gctgacgctg atatcttagg tgctgtagggt gctgccttcc 1080
agaatgagtg gttggcattc ggaggcaagc ggtggtatga ccgtgccact gctgatttca 1140
cacctcaacc agactttgag atacaacctg agcaacgtga agcactacgt ttcaaatatg 1200
gtacggatag gatgcagaca atcactgagg gtgttcgttc tgaggatgaa ttgaacttcc 1260
gtattcagaa tgccgatgaa gacottgagc gcaataagcg cattgctcag gctggctggg 1320
ttggctctgt ggcgacgatt ggcgctgctg tgcttgaccc tgtgggatgg gttgcctcta 1380
ttccaaccgg tgggtgccgt aaagttggac tcgtaggccg tgcgtgctgc ggcgctatcg 1440
ccgctggcgt gagtaatgcc gctattgaat ccgtattggg ccaaggtgac atgactcgtg 1500
atttagatga cattatggta gcactgggtt ccggtatggc tatgggtggc gttattggcg 1560
ctgtagcgcg tggtagggcc actaagctca gtgagcaagg tgatgacagg gctgctagca 1620
ttgtgcgcag tgcagacgca ggggaccgct atgttcgtgc tgttgccgat gacagtatcg 1680
gtgcgatgcg tgtaagggc gcagaggttc tctactgagg tgtattcgat atctccagta 1740
agagtgaaga cctactgaaa accttgcaac gagaaggtaa tgcgattgat atgacacctc 1800
gccgttgggc tggaactatg tctgccctcg gtactgtcgt gcactcatct aaagatgcaa 1860
gtatccgagg ccttgggtgct cgtctgtttg aatccccaca aggtctagggt atgcagaagg 1920
catctgctag tcttatgcag aatactaact taaatcgctt gaaatctgct gatatgaacc 1980
gcttcaatga tgggtttgat ttgtggctta aagagaataa tatcaatcca gtagcagggc 2040
ataccaactc tcattatgta cagcaatata atgaaaagggt gtgggaggca gtgcgtattg 2100
gcatggatga gtctacacct aaatctatcc gcatggctgc tgagggacaa caggctatgt 2160
acagagaggc gctggcttta cgtcaacgtt ctggtgaagc gggatttgaa aaggtaaaag 2220
ccgacaacaa atatatgcct gatattcttg atagtatgaa agccagacgt caattcgata 2280
tgcacgataa agaagacatc atcgaacttt tctctctgct ctaccagaat ggcgctcgta 2340
agattccaaa ggaagcagca gatgagattg cacgagcaca ggtaaatacg gttgctgatg 2400
ctaccttaac tggaaagctt agttttgaaa aggcaatgtc aggtcagact aaggcagagt 2460
atgaagctat catgcgtaag gcaggcttca gtgatgaaga aattgaaaag atgatagaag 2520
ctctggataa caaagaaacc agagataaca tctctaaccg agctaaaatg agtttaggat 2580
```

tagatgttac	tcaagaatac	aatggcattc	gtatgcgtga	cttcatgaat	accaacgtgg	2640
aagagctaac	agataactat	atgaaggaag	cagcaggtgg	cgctgcattg	gctcgccaag	2700
gcttctctac	ctatcaggct	gcacttaatg	caattgacct	tgtagagcga	aatgcacgaa	2760
acgcggctaa	ggatagcaag	gctagtttgg	cattagatga	agagattcgt	cagatgcgag	2820
aaggtcttcg	cctgattatg	ggcaagtcga	ttgatgcaga	cccacaggct	atatctacta	2880
agatgatgcg	tcgtggctgt	gatatcacag	gtgtgcttcg	cttaggtcaa	atgggcttcg	2940
cacagctagg	tgaacttgcc	aactttatgg	gtgaatttgg	tattgctgca	actactatgg	3000
ctttaggtaa	gcaattccgc	ttcacctcta	aggcgttgcg	taatggcgat	ggcttcttcc	3060
gagataagaa	cttagctgag	gttgagagaa	tgggtgggta	cattgggtgag	gataactggc	3120
taacaactaa	gggtgcacgt	cctgatgaat	ttgggtgatgt	aaccacagta	agagggatga	3180
tggctcactt	tgaccaatcc	atgaactcaa	tacgtcgtgc	tcaaaccaac	ctatcactct	3240
tccgcatggc	acagggttct	ctggagcgaa	tgactaatag	gcaaatagct	ttgtctttca	3300
ttgaccacct	tgaaggcaag	aagattattc	ctcagaagaa	actggaggaa	cttggcttta	3360
ctcaggagtt	catgactaac	ctacagaagc	actatgatgc	taactctaaa	ggttctggct	3420
tgcttggtct	tgatacaatg	ccttatgcc	tgggtgaaac	tttagctaat	gctattcgtc	3480
gtaagtcagg	tctaatacatc	caacgtaact	tcattgggtga	tgaaggatgc	tggatgaaca	3540
aagcactagg	taagacattt	gcacagctta	agtcattctc	tcttgatctc	ggtgagaagc	3600
aatttggtcg	agggattcgc	cacgataaaa	ttggtcttgc	taagaagaca	gcttacgggt	3660
ttgctttggg	ttcaatagtg	tatgcggcaa	aagcctatgt	gaactctatt	gggcgagaag	3720
accaagatga	atatttggaa	gagaagttat	cgcctaaagg	gttggccttt	ggtgcaatgg	3780
gttatccttg	tacaactgct	gtatttagtc	taggtggaga	tttcttaggt	ggcctagggt	3840
ttctaccttc	cgaactcatt	caatcacgct	atgaagcagg	tttccaaagt	aagggctctga	3900
ttgaccaaatt	acctctgggt	ggcgttgggt	cagatgcagt	aaatctggct	aactcaatca	3960
agaagtatgc	agaagggtgac	acagaagggtg	tagatatcgc	taagcgagca	ctccgtcttg	4020
tgccacttac	caatataata	ggtgtccaaa	acgcattgog	ttatggctta	gatgaactgg	4080
aggattgatg	agttatactt	tcacagaaca	tacagccaat	ggtacgcaag	tcacctatcc	4140
ttttagcttt	gctggtaggg	ataaaggtta	tcttcgtgoc	tcagatgtga	tagtggagtc	4200
tcttcaaggt	aacacttgga	ttgaagttac	atctggctgg	caactaactg	gcacgcacca	4260
gattactttt	gatgtagcac	cagttgcagg	tttgaagttc	cgtattcgaa	gggaagtaca	4320
aaaagaatat	ccatagctg	agtttgaccg	tggtgttacc	ttggatatga	agtcctttaa	4380
tggttctttc	attcatatgc	tggagattac	acaggagtta	cttgacgggt	tttatccaga	4440
aggatacttc	attaaacaga	atgtaagctg	gggcggaat	aagattactg	atttggctga	4500
tggcacaaat	ccgggagatg	cagtaaataa	agggcagctt	gatgccatcg	acaagaagca	4560
tacagattgg	aacgccaac	aggacattga	gattgctggc	cttaaggctg	gtatgacttc	4620
tggtattgcg	cacagaactg	ttccttggt	cacgatagcc	caagggtggt	agatttccgt	4680
aaaaccacct	tatgaatttc	aagatgcact	agttttcctt	aatgggggat	tcagcaccca	4740
aattgtaggc	gcatactcta	taagcaacaa	cactatcact	ttcgagagac	cgcttgtggc	4800
tggtacagag	gtgtatgtgc	tgattggtag	tcgttggtgt	acatctgaac	ctaataattca	4860
gttgagattg	aactttgact	tagtagaagg	ccaacaagta	gtacagattg	gctctgcatt	4920
taagtacatt	gaggtctacc	ttgatggatt	attacaacct	aaacttgctt	atcaggtaga	4980
cggtgacatt	gttactttct	cagaaagagt	accagaatgc	cggatgagtg	ctaagattat	5040
cacagcataa	ggaggtggga	tgattaactc	cgaactggta	gatagtgggt	tgaagcttgc	5100
gccacctgca	ctcatatcag	gtgggtactt	cctcggtatc	agttgggata	attgggtgtt	5160
aatagcaaca	ttcatttata	ccgtgttgca	aattggggac	tggttttata	ataagttcaa	5220
gatttgagg	gagaagcggt	agcgtacaca	ataaacatgc	agctacagag	gacgaggttg	5280
gcattctgca	tggtgctatt	accaaactct	tcaataagaa	agcacaggga	atactggaca	5340
ctatagaaga	agaccctgat	gcagcattac	atttagtgtc	tggtaaagat	attgggtgca	5400
tgtgtaagtg	ggttcttgat	aacggcatta	ccgccacacc	tgctgcacag	caggaaagag	5460
ccaagttatc	taagcgcctc	aaggctatcc	gagaggcatc	cagtggtaag	ataattcaat	5520
tcactaagga	ggattgatgg	ctaaggcaag	agaatcacaa	gcggaggctc	ttgccagatg	5580
ggagatgcta	caggagttac	agcagacctt	tccttacacc	gcggaagggt	tgcttctctt	5640
tgcagatata	gttattcata	acttaattgc	aggcaaccct	catctgatcc	gtatgcaggc	5700
ggatatcttg	aagttcctat	tttacggaca	caagtaccgc	ctcatcgaag	cgctcgtgg	5760
tatcgctaag	acaacactat	cagcaatcta	tacggtatcc	cgtattatcc	atgaaccgca	5820
taagcgtatc	atggttgtgt	cccaaaacgc	caagcgagca	gaggaaatcg	caggttgggt	5880
agttaaaatc	ttccgtgggt	tagactttct	tgagtttatg	ctgccggata	tctacgttgg	5940
ggaccgtgca	tccgttaagg	cgtttgagat	ctattacacc	ctacgtggt	gtgataagtc	6000
tccttctgta	tcctgttact	caatcgaagc	aggtatgcag	ggtgctcgtg	ctgatattat	6060

tctagcggat	gacgtagagt	cgatgcagaa	tgctcgtacg	gcagcggggc	gtgccttget	6120
tgaggagctg	actaaggagt	ttgaatctat	caaccagttt	ggggatatca	tttaccttgg	6180
tacacctcag	aacgtaaact	ctatctacaa	caacctacct	gctcgtgggt	actctgttcg	6240
tatctggact	gcgcgttacc	cttcagtaga	gcaagagcaa	tgttatggcg	acttccttgc	6300
acctatgatt	gttcaagata	tgaaggacaa	cccagcactt	cgctcagggt	acgggttgga	6360
tggtaatagt	ggtgcacctt	gtgcccctga	aatgtatgat	gatgaagtcc	tgattgagaa	6420
ggaaatctct	caggggtgctg	ctaagttcca	gcttcagttc	atgcttaaca	ctcgcatgat	6480
ggatgctgac	agatacccat	tacgcctgaa	caatctaate	ttcacctcgt	ttggtacaga	6540
ggaagtcctt	gtgatgccta	cgtggagtaa	tgattccata	aacatcattg	gtgatgcacc	6600
taagtatggt	aacaagccta	cggatttcat	gtacagacct	gtagctcgcc	catatgaatg	6660
gggtgctgtc	tcccgcgaaga	ttatgtatat	tgaccctgcg	ggtggtggtg	agaacggaga	6720
tgagacgggt	gtagccatcg	tattcctgca	cggcacattc	atttatgtgt	atcagtgtt	6780
tggtgtacct	ggcgataacc	gagagtcgtc	cctgaatcgc	attgtgcagg	ccgcaaagca	6840
ggcggtgtgt	aaagaggtat	tcattgagaa	gaactttggt	catggcgcgt	ttgaggcggt	6900
aattaagccg	tactttgaac	gagagtggcc	tgtaactctg	gaagaggatt	acgccaccgg	6960
acagaaagag	ttgcgtatca	ttgagacgct	ggagccgctc	atggcagccc	ataggcttat	7020
cttcaatgca	gagatggtga	agtcagactt	tgagtccgta	cagcactatc	cgcttgaact	7080
acgcatgtcc	tacagtcttt	tcaatcaaat	gtcgaacata	acgattgaga	agaacagcct	7140
ccggcacgat	gaccgcctag	acgccctgta	tggcgctata	cggcaattaa	cttctcagat	7200
agactatgac	gaggttacac	ggattaatcg	cctcagagcg	caggagatgc	gcgattacat	7260
ccatgctatg	aacacacctc	atctacgcag	ggcaatgcta	tatggagatt	acggtactga	7320
gcgaagagt	accaacactt	ccgtagcgat	cgcgacgca	gtttacgggc	agaactaccg	7380
aaataaatcg	gcaagcagaa	atacactttc	tgcaaggatt	tcaaggactt	attaattact	7440
ggacactata	gaaggaaggc	ccagataata	agagaaaata	ataggtaata	tatatatagg	7500
ttaacctagg	ttatataggt	atgccttagt	atgggtgtac	tcctgtacac	cctattcctt	7560
actaccttac	tatatattaca	taataggaga	gagacaatgg	ctaattgatta	tagtagtcaa	7620
ccattaacag	gtaagtctaa	gagaaagcag	gtacaacctg	taagtgaaga	actaatgctt	7680
ccggtgctca	aaaaagagga	agttagtaag	aaaagcaatg	ttattaatga	tgccaccaaa	7740
tcaggtaaac	agaaaggggc	catggtgtgc	cttgaagtga	aaggtggtgt	attgaagatt	7800
gctatcccg	ttgatggcaa	agaagattca	gagtggaaat	tagtaacagt	ggaaccaact	7860
gttaaccag	tttaagataa	ggaggaagat	tacatggcta	aatatggtac	tacaggttct	7920
gttactggtc	aggcttttcg	agtaaaagca	gtacaaacta	ttgcaacggc	aatcccgatg	7980
cctgttggtt	aagaagaaga	ccttaagagt	aaagaccacc	ctatcaacat	caaacattta	8040
tcaggtaaac	agaaaggtgc	aatggttgct	cttgagaaag	gtgacacaac	cttacatatt	8100
gctgttgcac	gtggttagtga	accacagac	ccttgggatg	taactggtat	ggaaaaggac	8160
gctgttactc	cagcaggggt	ataataatgc	ttataaata	cttcaagcgt	aaagagtttg	8220
cttgccgttg	tgggtgcggg	acatccactg	ttgatgctga	attactacag	gtagtcacag	8280
atgtgcgtga	gcactttggg	tctcctgtag	tatatcattc	gggtcatcgc	tgtgctaagc	8340
acaatgccaa	tgtaggtggc	gctaagaact	ccatgcactc	tactggtaag	gctgctgaca	8400
ttaaagtgtc	tggcatatta	ccttctgaag	tgcataagta	tcttactagc	aaataccaag	8460
gcaagtatgg	tataggtaag	tataactcct	tcactcacat	cgatgtacgg	gatggttgtg	8520
cgcgatggta	agatgtgttg	aatggtgtga	gcgtatgggt	gcccagctg	ccgaggatgg	8580
caactatgat	gactggaaga	actactctga	cttggttagct	caatggaaag	ggagatgcaa	8640
tgaaaaagct	gtttaagtct	aagaagggtg	taggtgcact	ggttgcactt	gttattgtct	8700
ttgtttctgt	aggtccttgg	gtagaccttg	gctctggcac	ggaatcctct	gtgacagatg	8760
tggtctgcca	agtgatcacc	tgtgaataag	tttctagaag	ttctggcagg	tcttattggc	8820
ctgcttgtct	ctgctaagaa	gaaacaagaa	gagaaggagg	cacaaagtga	agcgaatcat	8880
gttagtgaca	acccttctga	ttggttcgct	gaccacttcc	gggtgtcagc	aggcgttacc	8940
agagaaagca	atggtgaaac	ctctgaggcc	gacgctgacg	gcagtttacg	aggtagacga	9000
taaggctctgc	tttagtaagc	ctgacgctac	aaaacttggt	ttgtacattc	tctcgctaga	9060
acgcggatac	aattaatata	tagctttatg	tatcagtgct	ttacgattta	ctggacacta	9120
tagaagaggt	aagatagcgc	cgttcttttg	agcggcctat	tactagccaa	tcttcatagg	9180
gaggggttgga	aagtaatatg	agatagcatg	gctaaattaa	ccaaacctaa	tactgaagga	9240
atcttgcata	aaggacaatc	tttgtatgag	taccttgatg	cgagagtttt	aacatcaaag	9300
ccgtttgggtg	ctgcaggtga	cgccactact	gatgatacgg	aggttatagc	tgcttcatta	9360
aactctcaga	aagctgtcac	agtctcagat	ggtgtattct	ctagctctgg	tattaacagt	9420
aattactgta	acttagacgg	caggggtagt	ggcgtgctaa	gtcaccgttc	aagtacaggt	9480
aactacttag	tatttaacaa	tctacgtgca	ggctcgcttaa	gtaatattac	ggtagaaagt	9540

aataaggcga	ctgatacaac	tcagggacag	caggtatccc	ttgctgggtgg	aagtgatgtt	9600
actgtaagt	acgttaactt	ctcaaacgtt	aaaggtactg	gtttcagttt	aatcgcatat	9660
cctaatagat	cgccacctga	tggacttatg	attaaaggca	ttcgaggtag	ctattccggc	9720
tatgctacta	ataaggcagc	cggatgcgta	cttgcgtgatt	cctcagttaa	ctccctcata	9780
gataacgtca	ttgctaagaa	ctaccctcag	ttcggagcag	tagagttgaa	aggtacagcc	9840
agttacaaca	tagtcagtaa	tgttatagg	acagattgcc	agcatgtaac	ttacaacggc	9900
actgaagggc	caatagctcc	ttctaataac	cttatcaagg	gggtgatggc	taataaccct	9960
aagtatgcag	cggttgttgc	aggcaaagga	agtacgaact	taatctcaga	cgtgctcgta	10020
gattactcaa	cttctgatgc	taggcaggct	catggtgtta	cagtagaggg	ttctgataac	10080
gtcataaata	atgtgcttat	gtcaggatgt	gatggtagta	actctttagg	acaagggcag	10140
actgctacaa	ttgcacgctt	tataggtaca	gctaataaca	actatgcgtc	tgtatttcct	10200
agctacagtg	ctacagggtg	tattactttc	gaatccggct	ctaccgtaa	cttcgtagag	10260
gtaaagcacc	ctggcaggag	aaacgcacct	ctcagttctg	ctagtactat	tgacggtgca	10320
gctactattg	acggcaactag	taatagtaac	gtagtgcacg	cacctgcctt	agggcagtac	10380
ataggtagta	tgtcaggtag	gttcgaatgg	cggattaagt	ccatgtcact	cccttcaggc	10440
gttcttactt	ctgctgataa	gtacagaatg	cttgagatg	gtgctgtgtc	attagctgta	10500
gggtgggggca	cttctttctca	agttcgccta	tttacttctg	atggtagctt	tcggacagtg	10560
tccctcacca	acggtaacgt	gcgtctttct	accagtagca	caggcttttt	gcagttaggt	10620
gctgatgcaa	tgaccccgag	cagtagtgg	acatacgcat	taggttccgc	cagccgagca	10680
tggtctggcg	gttttactca	agcagcattc	actgttacct	cagatgctcg	gtgtaaaaca	10740
gaacctctta	ctatctcaga	tgcccttactg	gatgctttgg	ctgaagttga	ctttgtgca	10800
tttcagttat	tggatcgtgt	tgaggagaag	gggtcgagact	cagctagatg	gcacttcggt	10860
atcatcgctc	agcgagctaa	ggaggctttc	gaacgtcacg	gtatagatgc	acatcgctat	10920
ggcttcttgt	gcttcgacag	ttgggatgat	gtatacgagg	aagatgcaa	tggtctcgt	10980
aaactgatta	caccagcagg	ttcccgtctac	ggtattcgtt	acgaggaagt	actgatatta	11040
gaggctgcgt	tgatgcggcg	gactattaag	cgtatgcagg	aagcactagc	ttccctgcct	11100
aagtaagcaa	caggcagtg	gtaagcactg	cttttagcgc	aacttttctt	aaaggttatc	11160
acggtggtag	cctttcagaa	aaggaggtta	catgattcaa	agactagggt	cttcattagt	11220
taaattcaag	agtaaaatag	caggtgcaat	ctggcgtaac	ttggatgaca	agctcaccga	11280
ggttgtagtc	cttaagatt	ttggagccaa	aggtgatgg	aagacaaacg	accaagatgc	11340
agtaaatgca	gcgatggctt	caggtaagag	aattgacggt	gctgggtgcta	cttacaaggt	11400
atcatcttta	cctgatatgg	agcgattcta	taacacccgc	ttcgtatggg	aacgttttagc	11460
aggtcaacct	ctttactatg	tgagtaaagg	ttttatcaat	ggtgaactat	ataaaatcac	11520
ggataaccct	tattacaatg	cttggcctca	agacaaagcg	tttgatatatg	agaacgtgat	11580
atatgcacct	tacatgggta	gtgaccgtca	tggtgttagt	cgtctgcatg	tatcatgggt	11640
taagtctggt	gacgatggtc	aaacatggtc	tactccagag	tggttaactg	atctgcatcc	11700
agattaccct	acagtgaact	atcattgtat	gagtaggggt	gtatgtcgca	accgtctgtt	11760
tgccatgatt	gaaacacgta	cttttagccaa	gaacaaacta	accaattgtg	cattgtggga	11820
tcgccctatg	tctcgtatgc	tgcatcttac	tggtggtatc	actaaggctg	caaatcagca	11880
atatgcaaca	atacatgtac	cagatcacgg	actattcgtg	ggcgattttg	ttacttctc	11940
taattctgcg	gtaacagggtg	tatcagggtga	tatgactgtt	gcaacggtaa	tagataagga	12000
caacttcacg	gttcttacac	ctaaccagca	gacttcagat	ttgaataacg	ctggaaagag	12060
ttggcacatg	ggtacttctt	tccataagtc	tccatggcgt	aagacagatc	ttggtcta	12120
ccctagtgtc	acagagggtg	atagctttgc	tactattgat	aacaatggct	ttgttatggg	12180
ctatcatcaa	ggtgatgtag	ctccacgaga	agttgggtctt	ttctacttcc	ctgatgcttt	12240
caatagecca	tctaattatg	ttcgtcgtca	gataccatct	gagtagaac	cagatgcgtc	12300
agagccatgc	atcaagtact	atgacggtgt	attatacctt	atcactcgtg	gcactcttgg	12360
tgacagactt	ggaagctctt	tgcatcgtag	tagagatata	ggtcagactt	gggagtcact	12420
gagatttcca	cataatgttc	atcatactac	cctacctttt	gctaaagtag	gagatgacct	12480
tattatgttt	ggttcagaac	gtgcagaaaa	tgaatgggaa	gcaggtgcac	cagatgatcg	12540
ttacaaggca	tcttatcctc	gtaccttcta	tgacagattg	aatgtaaaca	attggaatgc	12600
agatgatatt	gaatgggtta	acatcacaga	ccaaatctat	caaggtgaca	ttgtgaactc	12660
tagtgtaggt	gtaggttcgg	tagtagtta	agacagctac	atttactata	tctttgggtg	12720
cgaaaaccat	ttcaacccaa	tgacttatgg	tgacaacaaa	ggtaaagacc	catttaaagg	12780
tcatggacac	cctactgata	tatactgcta	taagatgcag	attgcaaatg	acaatcgtgt	12840
atctcgtaag	tttactatg	gtgcaactcc	gggtcaagct	atacctactt	tcatgggtag	12900
tgatggaata	cgaaatatcc	ctgcaccttt	gtatttctca	gataacattg	ttacagagga	12960
tactaaagtt	ggacacttaa	cacttaaagc	aagcacaagt	tccaatatac	gatctgaagt	13020

```

gcagatggaa ggtgaatatg gctttattgg caagtctgtt ccaaaggaca acccaactgg 13080
tcaacgtttg attatttgtg gtggagaaga gacttcgtcc tcttcagggtg cacagataac 13140
tttgacggc tctaattcaa gtaaggctaa tcgtatcact tataacggaa atgagcacct 13200
attccaaggt gcaccaatca tgcttctgt agataaccag tttgctgctg gtggacctag 13260
taaccgattc actaccatct acctaggtag tgaccctgtt acaacttcag atgctgacca 13320
caagtacagt atctctagta ttaataccaa ggtgttaaag gcttggagca gggttgggtt 13380
taaacagtat ggtttgaata gtgaagcaga gagggacctt gatagcatac acttcggtgt 13440
cttggctcag gatattgtag ctgcttttga agctgaagggt ttggatgcc a ttaagtatgg 13500
aattgtgtcc ttcgaagaag gtaggtacgg tgtgaggtat agtgaagttc taataactaga 13560
ggctgcttat actcgttata gtttagacaa gtttagaggag atgtatgcc a ctaataaaat 13620
cagttaagca agctgctgta ctccagaaca cagaagagct tattcaatca ggacgtgacc 13680
ctaagcaggc ttatgccatt gcccaaggatg ttcaacgtcg tgccatgaag aaaccttctg 13740
catcttctgc gtaagcaggt taatatctta gtataaaciaa gggcagactt aggtttgtcc 13800
ttagtgtatt ccaaaggagg taacatgctg aaagatggtt gggtttcata tgacctaca 13860
gacctaaaga attggctaca ggttatcgct atagcttgtg caggtagcct attggctgcc 13920
ctgatgtatt cattatggat gtacacaaag taaccaaagt caaaattttg atgtaggcgt 13980
gtgtcagctc tctcgccctc gccctcgccg ggttgtcccc atagggtggc ctgagggaat 14040
ccgtcttcga cgggcagggc tgatgtactc cttgtctagt acaaggagg cggagggaac 14100
gcctaggagg gcctaggaat ggcttagtggt tggacaaggt gattacctta gtgaagcctc 14160
ttagtgcat cctgaggcca ttcagggcgt ttatgaggga ttgacagggt gtgagggcgt 14220
gggcta

```


(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/007742 A3

(51) International Patent Classification⁷: **A61K 35/76**,
C12N 7/00, 15/86, A61P 31/04, A61K 48/00

(21) International Application Number: PCT/US01/23390

(22) International Filing Date: 25 July 2001 (25.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/220,987 25 July 2000 (25.07.2000) US

(71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 25, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MERRIL, Carl, R.** [US/US]; 6840 Capri Place, Rockville, MD 20817 (US). **ADHYA, Sankar** [US/US]; 14400 Kings Grant Road, Gaithersburg, MD 20870 (US). **SCHOLL, Deal** [US/US]; 10416 Fawcett Street, #2, Kensington, MD 20895 (US).

(74) Agent: **ALTMAN, Daniel, E.**; Knobbe, Martens, Olson and Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), DE (utility model), DK (utility model), DM, DZ, EC, EE (utility model), ES, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
8 August 2002

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 16/2002 of 18 April 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BACTERIOPHAGE HAVING MULTIPLE HOST RANGE

(57) Abstract: The present invention discloses compositions and methods for the prophylaxis and treatment of bacterial infections by the use of polyvalent bacteriophage having multiple host range.

WO 02/007742 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/23390

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K35/76 C12N7/00 C12N15/86 A61P31/04 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

SEQUENCE SEARCH, CHEM ABS Data, SCISEARCH, EMBASE, BIOSIS, MEDLINE, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CAO J ET AL: "Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth" BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1474, no. 1, 6 March 2000 (2000-03-06), pages 107-113, XP004276546 ISSN: 0304-4165 abstract	1-34, 37-40
Y	W0 97 29185 A (MAARDH SVEN) 14 August 1997 (1997-08-14) claim 1	1-34, 37-40
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

16 May 2002

Date of mailing of the international search report

31/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Niemann, F

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 01/23390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TETART F ET AL: "Bacteriophage T4 host range is expanded by duplications of a small domain of the tail fiber adhesin." JOURNAL OF MOLECULAR BIOLOGY, vol. 258, no. 5, 1996, pages 726-731, XP002199086 ISSN: 0022-2836 cited in the application abstract page 730, left-hand column, paragraph 2 -right-hand column, paragraph 1 ---	1-34, 37-40
Y	TETART F ET AL: "GENOME PLASTICITY IN THE DISTAL TAIL FIBER LOCUS OF THE T-EVEN BACTERIOPHAGE: RECOMBINATION BETWEEN CONSERVED MOTIFS SWAPS ADHESINSPECIFICITY" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 282, no. 3, 1998, pages 543-556, XP000920896 ISSN: 0022-2836 cited in the application abstract page 543, right-hand column, paragraph 2 ---	1-34, 37-40
A	BARROW P A ET AL: "BACTERIOPHAGE THERAPY AND PROPHYLAXIS: REDISCOVERY AND RENEWED ASSESSMENT OF POTENTIAL" TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 5, 1997, pages 268-271, XP000993117 ISSN: 0966-842X cited in the application the whole document ---	1-34, 37-40
A	MERRIL C R ET AL: "LONG-CIRCULATING BACTERIOPHAGE AS ANTIBACTERIAL AGENTS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 8, 16 April 1996 (1996-04-16), pages 3188-3192, XP002044135 ISSN: 0027-8424 the whole document ---	1-34, 37-40
P,X	SCHOLL DEAN ET AL: "Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli." JOURNAL OF VIROLOGY, vol. 75, no. 6, March 2001 (2001-03), pages 2509-2515, XP002199087 ISSN: 0022-538X the whole document ---	1-34, 37-40

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/23390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 21007 A (VIAGENE INC) - 11 July 1996 (1996-07-11) the whole document ---	35, 36
X	WO 98 05344 A (BRIGHAM & WOMENS HOSPITAL ; SARKAR SAUMYENDRA N (US); DUBIN DANIEL) 12 February 1998 (1998-02-12) the whole document -----	35, 36

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-34,37-40

a pharmaceutical composition comprising a phage having multiple host specificity based on having multiple host tail proteins and a pharmaceutically acceptable excipient

2. Claims: 35,36

a pharmaceutical composition comprising a phage having mammalian host specificity by presenting on the tail of said phage a mammalian cell surface-receptor ligand, wherein the phage genome encodes a therapeutic gene product

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/23390

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9729185	A	14-08-1997	SE 506771 C2	09-02-1998
			AU 712767 B2	18-11-1999
			AU 1681797 A	28-08-1997
			CA 2244792 A1	14-08-1997
			CN 1210558 A	10-03-1999
			EP 0889955 A1	13-01-1999
			HU 9901242 A2	28-07-1999
			JP 2000505648 T	16-05-2000
			NO 983456 A	06-10-1998
			NZ 331580 A	29-09-1999
			SE 9600434 A	07-08-1997
			WO 9729185 A1	14-08-1997
			US 2002044922 A1	18-04-2002
WO 9621007	A	11-07-1996	US 5736388 A	07-04-1998
			AU 4610396 A	24-07-1996
			WO 9621007 A2	11-07-1996
WO 9805344	A	12-02-1998	AU 3737297 A	25-02-1998
			WO 9805344 A1	12-02-1998